1
|
Chen X, Li X, Wang J, Zhao L, Peng X, Zhang C, Liu K, Huang G, Lai Y. Breast invasive ductal carcinoma diagnosis with a three-miRNA panel in serum. Biomark Med 2021; 15:951-963. [PMID: 34293926 DOI: 10.2217/bmm-2020-0785] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
Aim: Breast cancer, especially invasive ductal carcinoma (IDC), is the cause of a great clinical burden. miRNA could be considered as a noninvasive biomarkers for IDC diagnosis. Materials & methods: Two hundred and sixty participants (135 IDC patients and 125 healthy controls) were enrolled in a three-cohort study. The expression of 28 miRNAs in serum were detected with quantitative reverse transcription-PCR. Bioinformatic analysis was used for predicting the target genes of three selected miRNAs. Results: The expression level of seven miRNAs (miR-9-5p, miR-34b-3p, miR-1-3p, miR-146a-5p, miR-20a-5p, miR-34a-5p, miR-125b-5p) was discrepant at the validation cohort. Through statistical test, a three-miRNA panel (miR-9-5p, miR-34b-3p, miR-146a-5p) was significant for IDC diagnosis (AUC = 0.880, sensitivity = 86.25%, specificity = 81.25%). Conclusion: The three-miRNA panel in serum could be used as a noninvasive biomarker in the diagnosis of IDC.
Collapse
Affiliation(s)
- Xuan Chen
- Shantou University Medical College, Shantou, Guangdong, 515041, China
- Department of Urology, Guangdong & Shenzhen Key Laboratory of Male Reproductive Medicine & Genetics, Peking University Shenzhen Hospital, Shenzhen, Guangdong, 518036, China
| | - Xinji Li
- Shantou University Medical College, Shantou, Guangdong, 515041, China
- Department of Urology, Guangdong & Shenzhen Key Laboratory of Male Reproductive Medicine & Genetics, Peking University Shenzhen Hospital, Shenzhen, Guangdong, 518036, China
| | - Jingyao Wang
- Department of Urology, Guangdong & Shenzhen Key Laboratory of Male Reproductive Medicine & Genetics, Peking University Shenzhen Hospital, Shenzhen, Guangdong, 518036, China
| | - Liwen Zhao
- Department of Urology, Guangdong & Shenzhen Key Laboratory of Male Reproductive Medicine & Genetics, Peking University Shenzhen Hospital, Shenzhen, Guangdong, 518036, China
- Anhui Medical University, Hefei, Anhui, 230032, China
| | - Xiqi Peng
- Shantou University Medical College, Shantou, Guangdong, 515041, China
- Department of Urology, Guangdong & Shenzhen Key Laboratory of Male Reproductive Medicine & Genetics, Peking University Shenzhen Hospital, Shenzhen, Guangdong, 518036, China
| | - Chunduo Zhang
- Department of Urology, Guangdong & Shenzhen Key Laboratory of Male Reproductive Medicine & Genetics, Peking University Shenzhen Hospital, Shenzhen, Guangdong, 518036, China
| | - Kaihao Liu
- Department of Urology, Guangdong & Shenzhen Key Laboratory of Male Reproductive Medicine & Genetics, Peking University Shenzhen Hospital, Shenzhen, Guangdong, 518036, China
- Anhui Medical University, Hefei, Anhui, 230032, China
| | - Guocheng Huang
- Shantou University Medical College, Shantou, Guangdong, 515041, China
- Department of Urology, Guangdong & Shenzhen Key Laboratory of Male Reproductive Medicine & Genetics, Peking University Shenzhen Hospital, Shenzhen, Guangdong, 518036, China
| | - Yongqing Lai
- Department of Urology, Guangdong & Shenzhen Key Laboratory of Male Reproductive Medicine & Genetics, Peking University Shenzhen Hospital, Shenzhen, Guangdong, 518036, China
| |
Collapse
|
2
|
Dąbrowska E, Przylipiak A, Zajkowska M, Piskór BM, Borowik-Zaręba A, Ławicki S. C-C motif chemokine ligand 5 and C-C chemokine receptor type 5: possible diagnostic application in breast cancer patients. Acta Biochim Pol 2020; 67:539-449. [PMID: 33245226 DOI: 10.18388/abp.2020_5402] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2020] [Accepted: 08/31/2020] [Indexed: 11/10/2022]
Abstract
The chemokine CCL5 and its receptor CCR5 play important roles in cancer invasion and metastasis. Based on our knowledge, our results were the first that presented the diagnostic usefulness of CCL5 and CCR5 in breast cancer (BC) patients, based on receiver operating characteristic (ROC) curve analysis. We wished to examine further if CCL5 and CCR5 are appropriate to be applied as BC markers for early screening. Values of tested parameters in patients' plasma were determined by CMIA method (Chemiluminescent Microparticle Immunoassay, CA 15-3) as well as by ELISA method (Enzyme-Linked Immunosorbent Assay, CCL5 and CCR5). Levels of CCL5 in the plasma were markedly increased, while those of CCR5 were remarkably lower in BC patients when compared to the control groups. Moreover, higher levels of CCL5 in BC corresponded to advanced tumor stage, while the levels of CCR5 decreased with increasing the disease stage. CCL5 concentration was characterized by high sensitivity (SE) (68.04%) and high specificity (SP) (100.00%) in the BC patients. Results indicated that area under the curve (AUC) corresponding to CCL5 (0.8116) had a higher value than this corresponding to CA 15-3. The AUC value of CCL5 was significantly increased in the early phase of BC (stage I - 0.7089; stage II - 0.8313). The maximum range in the BC patients was observed for the combined analysis of the tested measurands with CA 15-3 (0.8335). In conclusion, our research indicates that examination of plasma CCL5 and CCR5 may be useful in BC diagnosis at the early stage of the disorder, especially when combined with CA 15-3.
Collapse
MESH Headings
- Adult
- Aged
- Aged, 80 and over
- Area Under Curve
- Biomarkers, Tumor/blood
- Biomarkers, Tumor/genetics
- Breast Neoplasms/blood
- Breast Neoplasms/diagnosis
- Breast Neoplasms/genetics
- Breast Neoplasms/mortality
- Carcinoma, Ductal, Breast/blood
- Carcinoma, Ductal, Breast/genetics
- Carcinoma, Ductal, Breast/mortality
- Case-Control Studies
- Chemokine CCL5/blood
- Chemokine CCL5/genetics
- Early Detection of Cancer/methods
- Female
- Gene Expression
- Humans
- Middle Aged
- Mucin-1/blood
- Mucin-1/genetics
- Neoplasm Staging
- Prognosis
- ROC Curve
- Receptors, CCR5/blood
- Receptors, CCR5/genetics
- Survival Analysis
Collapse
Affiliation(s)
- Emilia Dąbrowska
- Department of Esthetic Medicine, Medical University of Bialystok, Białystok, Poland
| | - Andrzej Przylipiak
- Department of Esthetic Medicine, Medical University of Bialystok, Białystok, Poland
| | - Monika Zajkowska
- Department of Biochemical Diagnostics, Medical University of Bialystok, Białystok, Poland
| | - Barbara Maria Piskór
- Department of Esthetic Medicine, Medical University of Bialystok, Białystok, Poland
| | | | - Sławomir Ławicki
- Department of Population Medicine and Civilization Diseases Prevention, Medical University of Bialystok, Białystok, Poland
| |
Collapse
|
3
|
Zheng L, Zhao Y, Liu F, Liu P, Li W, Yang Y, Zhang H, Liu Y. Prognostic significance of preoperative albumin to fibrinogen ratio associated nomograms in patients with breast invasive ductal carcinoma. Medicine (Baltimore) 2020; 99:e20681. [PMID: 32590741 PMCID: PMC7328933 DOI: 10.1097/md.0000000000020681] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
Plasma albumin to fibrinogen ratio is involved in human cancer, but its prognostic significance in breast cancer is controversy. In the context of breast invasive ductal carcinoma, this research aims to retrospectively evaluate by preoperative plasma albumin to fibrinogen ratio (AFR) and forecast oncological outcome and recurrence.This retrospective study comprised 230 patients with non-metastatic breast invasive ductal carcinoma who underwent surgery between January 2009 and April 2012 in Fourth Hospital of Hebei Medical University. Patients were categorized base on an optimal value of preoperative plasma fibrinogen (Fib) and albumin. Progression-free and cancer-specific survival were assessed using Kaplan-Meier method. The associations between albumin to fibrinogen ratio and clinical outcomes were assessed with univariate and multivariate analysis. A number of risk factors were used to form nomograms to evaluate survival, and Harrell concordance index (C-index) was used to evaluate the predictive accuracy.Plasma AFR was significantly associated with diminished disease-free survival (DFS) and overall survival (OS). Multivariate analysis revealed that plasma AFR was an independent prognostic indicator for DFS (HR = 1.346; 95% CI: 1.107-1.636; P = .03) and overall survival (OS) (HR = 1.485; 95% CI: 1.106-1.993; P = .008). Two prediction model of 3-, 5-years OS and DFS based on the AFR was developed.Elevated preoperative plasma AFR is an independent prognostic factor for oncological outcomes in patients with breast invasive ductal carcinoma. The formulated nomogram showed superior predictive accuracy for DFS and OS.
Collapse
Affiliation(s)
- Lihua Zheng
- Department of General Surgery, Hebei Key Laboratory of Colorectal Cancer Precision Diagnosis and Treatment
- Department of Vascular Surgery
- Department of General Surgery, the First Hospital of Hebei Medical University, Hebei, Shijiazhuang, China
| | - Yaheng Zhao
- Department of General Surgery, Hebei Key Laboratory of Colorectal Cancer Precision Diagnosis and Treatment
- Department of Vascular Surgery
- Department of General Surgery, the First Hospital of Hebei Medical University, Hebei, Shijiazhuang, China
| | - Feng Liu
- Department of General Surgery, Hebei Key Laboratory of Colorectal Cancer Precision Diagnosis and Treatment
- Department of Vascular Surgery
- Department of General Surgery, the First Hospital of Hebei Medical University, Hebei, Shijiazhuang, China
| | - Peng Liu
- Department of General Surgery, Hebei Key Laboratory of Colorectal Cancer Precision Diagnosis and Treatment
- Department of Vascular Surgery
- Department of General Surgery, the First Hospital of Hebei Medical University, Hebei, Shijiazhuang, China
| | - Wei Li
- Department of General Surgery, Hebei Key Laboratory of Colorectal Cancer Precision Diagnosis and Treatment
- Department of Vascular Surgery
- Department of General Surgery, the First Hospital of Hebei Medical University, Hebei, Shijiazhuang, China
| | - Yan Yang
- Department of General Surgery, Hebei Key Laboratory of Colorectal Cancer Precision Diagnosis and Treatment
- Department of Vascular Surgery
- Department of General Surgery, the First Hospital of Hebei Medical University, Hebei, Shijiazhuang, China
| | - Hongsong Zhang
- Department of General Surgery, Hebei Key Laboratory of Colorectal Cancer Precision Diagnosis and Treatment
- Department of Vascular Surgery
- Department of General Surgery, the First Hospital of Hebei Medical University, Hebei, Shijiazhuang, China
| | - Yunjiang Liu
- Department of Breast Surgery, the Fourth Hospital of Hebei Medical University
| |
Collapse
|
4
|
Lee SB, Bose S, Ahn SH, Son BH, Ko BS, Kim HJ, Chung IY, Kim J, Lee W, Ko MS, Lee K, Chang S, Park HS, Lee JW, Kim DC. Breast cancer diagnosis by analysis of serum N-glycans using MALDI-TOF mass spectroscopy. PLoS One 2020; 15:e0231004. [PMID: 32271809 PMCID: PMC7144955 DOI: 10.1371/journal.pone.0231004] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2019] [Accepted: 03/13/2020] [Indexed: 12/12/2022] Open
Abstract
Blood and serum N-glycans can be used as markers for cancer diagnosis, as alterations in protein glycosylation are associated with cancer pathogenesis and progression. We aimed to develop a platform for breast cancer (BrC) diagnosis based on serum N-glycan profiles using MALDI-TOF mass spectroscopy. Serum N-glycans from BrC patients and healthy volunteers were evaluated using NosQuest’s software “NosIDsys.” BrC-associated “NosID” N-glycan biomarkers were selected based on abundance and NosIDsys analysis, and their diagnostic potential was determined using NosIDsys and receiver operating characteristic curves. Results showed an efficient pattern recognition of invasive ductal carcinoma patients, with very high diagnostic performance [area under the curve (AUC): 0.93 and 95% confidence interval (CI): 0.917–0.947]. We achieved effective stage-specific differentiation of BrC patients from healthy controls with 82.3% specificity, 84.1% sensitivity, and 82.8% accuracy for stage 1 BrC and recognized hormone receptor-2 and lymph node invasion subtypes based on N-glycan profiles. Our novel technique supplements conventional diagnostic strategies for BrC detection and can be developed as an independent platform for BrC screening.
Collapse
Affiliation(s)
- Sae Byul Lee
- Division of Breast Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
| | - Shambhunath Bose
- R&D Center, NOSQUEST Inc., Seongnam, Gyeonggi, Republic of Korea
| | - Sei Hyun Ahn
- Division of Breast Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
| | - Byung Ho Son
- Division of Breast Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
| | - Beom Seok Ko
- Division of Breast Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
| | - Hee Jeong Kim
- Division of Breast Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
| | - Il Yong Chung
- Division of Breast Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
| | - Jisun Kim
- Division of Breast Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
| | - Woochang Lee
- Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
| | - Myung-Su Ko
- Health Screening and Promotion Center, Asan Medical Center, Seoul, Republic of Korea
| | - Kyungsoo Lee
- R&D Center, NOSQUEST Inc., Seongnam, Gyeonggi, Republic of Korea
| | - Suhwan Chang
- Department of Biomedical Sciences, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
| | | | - Jong Won Lee
- Division of Breast Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
- * E-mail: (JWL); (DCK)
| | - Dong-Chan Kim
- R&D Center, NOSQUEST Inc., Seongnam, Gyeonggi, Republic of Korea
- * E-mail: (JWL); (DCK)
| |
Collapse
|
5
|
Kloudova-Spalenkova A, Ueng YF, Wei S, Kopeckova K, Peter Guengerich F, Soucek P. Plasma oxysterol levels in luminal subtype breast cancer patients are associated with clinical data. J Steroid Biochem Mol Biol 2020; 197:105566. [PMID: 31874216 PMCID: PMC7015808 DOI: 10.1016/j.jsbmb.2019.105566] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/05/2019] [Revised: 12/11/2019] [Accepted: 12/16/2019] [Indexed: 02/06/2023]
Abstract
Oxygenated metabolites of cholesterol (oxysterols) have been previously demonstrated to contribute to progression of various cancers and to modulate resistance to breast cancer endocrine therapy in vitro. We measured prognostic roles of circulating levels of seven major oxysterols in the progression of luminal subtype breast carcinoma. Liquid chromatography coupled with tandem mass spectrometry was used for determination of levels of non-esterified 25-hydroxycholesterol, 27-hydroxycholesterol, 7α-hydroxycholesterol, 7-ketocholesterol, cholesterol-5α,6α-epoxide, cholesterol-5β,6β-epoxide, and cholestane-3β,5α,6β-triol in plasma samples collected from patients (n = 58) before surgical removal of tumors. Oxysterol levels were then associated with clinical data of patients. All oxysterols except cholesterol-5α,6α-epoxide were detected in patient plasma samples. Circulating levels of 7α-hydroxycholesterol and 27-hydroxycholesterol were significantly lower in patients with small tumors (pT1) and cholesterol-5β,6β-epoxide and cholestane-3β,5α,6β-triol were lower in patients with stage IA disease compared to larger tumors or more advanced stages. Patients with higher than median cholestane-3β,5α,6β-triol levels had significantly worse disease-free survival than patients with lower levels (p = 0.037 for all patients and p = 0.015 for subgroup treated only with tamoxifen). In conclusion, this study shows, for the first time, that circulating levels of oxysterols, especially cholestane-3β,5α,6β-triol, may have prognostic roles in patients with luminal subtype breast cancer.
Collapse
Affiliation(s)
- Alzbeta Kloudova-Spalenkova
- Department of Toxicogenomics, National Institute of Public Health, Srobarova 48, Prague 10, 10042, Czech Republic; Biomedical Centre, Faculty of Medicine Pilsen, Charles University, alej Svobody 1655/76, Pilsen, 32300, Czech Republic; Third Faculty of Medicine, Charles University, Ruska 2411/87, Prague 10, 10000, Czech Republic
| | - Yune-Fang Ueng
- National Research Institute of Chinese Medicine, Taipei, Taiwan, ROC; Department and Institute of Pharmacology, School of Medicine, National Yang-Ming University, Taipei, Taiwan, ROC; Institute of Medical Sciences, Taipei Medical University, Taipei, Taiwan, ROC
| | - Shouzou Wei
- Department of Medicine, Vanderbilt University Medical Center, 2200 Pierce Avenue, Nashville, TN, 37235, United States
| | - Katerina Kopeckova
- Department of Oncology, Second Faculty of Medicine, Charles University and Motol University Hospital, V Uvalu 84/1, 15000, Prague 5, Czech Republic
| | - F Peter Guengerich
- Department of Biochemistry, Vanderbilt University School of Medicine, 2200 Pierce Avenue, Nashville, TN, 37232-0146, United States
| | - Pavel Soucek
- Biomedical Centre, Faculty of Medicine Pilsen, Charles University, alej Svobody 1655/76, Pilsen, 32300, Czech Republic.
| |
Collapse
|
6
|
Jansson M, Billing O, Herdenberg C, Lundin C, Tolockiene E, Nazemroaya A, Sund M. Expression and Circulating Levels of Perlecan in Breast Cancer - Implications for Oestrogen Dependent Stromal Remodeling. J Mammary Gland Biol Neoplasia 2020; 25:69-77. [PMID: 32124140 DOI: 10.1007/s10911-020-09447-2] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/25/2019] [Accepted: 02/18/2020] [Indexed: 12/12/2022] Open
Abstract
Localised breast cancer can be cured by surgery and adjuvant treatments, but mortality remains high as some tumours metastasize early. Perlecan is a basement membrane (BM) protein involved in tumour development and progression. Here, mRNA and protein expression of perlecan, and mRNA expression of matrix degrading enzymes were studied in normal breast and invasive breast cancer, and correlated to prognostic risk factors, in particular oestrogen status. Moreover, plasma levels of perlecan were measured in patients with breast cancer and compared with controls. mRNA data was extracted from the Cancer Genome Atlas database. Perlecan protein expression was visualized using immunofluorescence and plasma levels measured by ELISA assay. Perlecan mRNA levels were twice as high in normal breast compared with breast cancer tissue. A strong correlation was found between mRNA expression of perlecan and several matrix-degrading enzymes in oestrogen receptor positive (ER+) tumours. Perlecan protein was localized to both epithelial and vascular BMs, but absent in the stroma in normal breast. In breast cancer, the expression of perlecan in epithelial BM was fragmented or completely lost, with a marked upregulation of perlecan expression in the stroma. Significantly higher levels of perlecan were found in plasma of ER+ patients when compared with ER- patients. This study shows that perlecan expression and degradation in breast cancer may be linked to the ER status of the tumour.
Collapse
MESH Headings
- Biomarkers, Tumor/blood
- Biomarkers, Tumor/genetics
- Breast Neoplasms/blood
- Breast Neoplasms/genetics
- Breast Neoplasms/pathology
- Carcinoma, Ductal, Breast/blood
- Carcinoma, Ductal, Breast/genetics
- Carcinoma, Ductal, Breast/pathology
- Carcinoma, Lobular/blood
- Carcinoma, Lobular/genetics
- Carcinoma, Lobular/pathology
- Case-Control Studies
- Cohort Studies
- Extracellular Matrix Proteins/genetics
- Extracellular Matrix Proteins/metabolism
- Female
- Follow-Up Studies
- Heparan Sulfate Proteoglycans/blood
- Heparan Sulfate Proteoglycans/genetics
- Humans
- Middle Aged
- Prognosis
- Receptor, ErbB-2/metabolism
- Receptors, Estrogen/metabolism
- Receptors, Progesterone/metabolism
- Stromal Cells/metabolism
- Stromal Cells/pathology
Collapse
Affiliation(s)
- Malin Jansson
- Department of Surgery and Perioperative Sciences/Surgery, Umeå University, 90185, Umeå, Sweden.
| | - Ola Billing
- Department of Surgery and Perioperative Sciences/Surgery, Umeå University, 90185, Umeå, Sweden
| | - Carl Herdenberg
- Department of Radiation Sciences/Oncology, Umeå University, 90185, Umeå, Sweden
| | - Christina Lundin
- Department of Surgery and Perioperative Sciences/Surgery, Umeå University, 90185, Umeå, Sweden
| | - Egle Tolockiene
- Department of Medical Biosciences/Pathology, Umeå University, 90185, Umeå, Sweden
| | - Anoosheh Nazemroaya
- Department of Medical Biosciences/Pathology, Umeå University, 90185, Umeå, Sweden
| | - Malin Sund
- Department of Surgery and Perioperative Sciences/Surgery, Umeå University, 90185, Umeå, Sweden
| |
Collapse
|
7
|
Tang S, Zheng K, Tang Y, Li Z, Zou T, Liu D. Overexpression of serum exosomal HOTAIR is correlated with poor survival and poor response to chemotherapy in breast cancer patients. J Biosci 2019; 44:37. [PMID: 31180050] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Abstract
To investigate the source of serum exosomal HOTAIR, to uncover the diagnostic and prognostic values of serum exosomal HOTAIR, and to discern the expression of serum exosomal HOTAIR between neoadjuvant chemotherapy and response to tamoxifen therapy. Samples were collected from the Third Affiliated Hospital of Kunming Medical University, Tumor Hospital of Yunnan. Exosomes were isolated from serum, cell culture medium and tumor tissues. We used transmission electron microscopy and western immunoblotting assay to characterize exosomes, and real-time PCR (qPCR) to assess HOTAIR expression. Neoadjuvant chemotherapy and tamoxifen therapy were carried out according to established guidelines. Breast cancer patients expressed higher serum exosomal HOTAIR than did healthy individuals (P\0.001). Serum exosomal HOTAIR levels 3 months after surgery were markedly decreased compared with levels before surgery (P\0.001), and the expression level of exosomal HOTAIR in cell culture medium increased with time in both breast cancer cell lines (72 h greater than 48 h greater than 24 h, 48 h vs 24 h [ [P less than 0.05]; 72 h vs 24 h [P less than 0.01]. Expression of serum exosomal HOTAIR in nude mice was notably greater than in the mock control group (P less than 0.001). The results of the ROC analysis revealed an AUC for serum exosomal HOTAIR of 0.9178 with a 95% CI of 0.8407-1.017 (P less than 0.01). The AUC for the CA15-3 cell line was 0.7378 (95% CI, 0.5585-0.9170; P = 0.03). High expression of exosomal HOTAIR led to a worse disease-free survival (P = 0.0481) and overall survival (P = 0.0463). In the high-expression chemotherapy group, six patients achieved a partial response (PR) and eight demonstrated stable disease (SD) and nine patients achieved PR and two SD in the low-expression group (P = 0.048). In the low-expression tamoxifen group, one patient had a recurrence of breast cancer and another 10 patients exhibited no recurrence, while six showed recurrence, and seven had none in the highexpression group (P = 0.035). We isolated exosomes successfully, and demonstrated that serum exosomal HOTAIR originated from primary breast cancer tissue. We conclude that serum exosomal HOTAIR exhibits the potential to be a diagnostic and prognostic biomarker. High expression of serum exosomal HOTAIR was also correlated with poor neoadjuvant chemotherapy and response to tamoxifen therapy.
Collapse
MESH Headings
- Adult
- Aged
- Animals
- Antineoplastic Agents/therapeutic use
- Antineoplastic Combined Chemotherapy Protocols/therapeutic use
- Breast Neoplasms/blood
- Breast Neoplasms/drug therapy
- Breast Neoplasms/genetics
- Breast Neoplasms/mortality
- Carcinoma, Ductal, Breast/blood
- Carcinoma, Ductal, Breast/drug therapy
- Carcinoma, Ductal, Breast/genetics
- Carcinoma, Ductal, Breast/mortality
- Carcinoma, Lobular/blood
- Carcinoma, Lobular/drug therapy
- Carcinoma, Lobular/genetics
- Carcinoma, Lobular/mortality
- Cell Differentiation/drug effects
- Cell Line, Tumor
- Cell Proliferation/drug effects
- Exosomes/chemistry
- Exosomes/metabolism
- Female
- Gene Expression Regulation, Neoplastic
- Humans
- Mice
- Mice, Nude
- Middle Aged
- RNA, Long Noncoding/genetics
- RNA, Long Noncoding/metabolism
- Signal Transduction
- Survival Analysis
- Tamoxifen/therapeutic use
- Xenograft Model Antitumor Assays
Collapse
Affiliation(s)
- Shicong Tang
- Department of Breast Surgery, The Third Affiliated Hospital of Kunming Medical University, Tumor Hospital of Yunnan, Kunming, Yunnan, People's Republic of China
| | | | | | | | | | | |
Collapse
|
8
|
Macías-Gómez NM, Hernández-Terrones MC, Ramírez-Guerrero AA, Leal-Ugarte E, Gutiérrez-Angulo M, Peregrina-Sandoval J. ADIPOQ rs2241766 SNP as protective marker against DIBC development in Mexican population. PLoS One 2019; 14:e0214080. [PMID: 30883598 PMCID: PMC6422300 DOI: 10.1371/journal.pone.0214080] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2018] [Accepted: 03/06/2019] [Indexed: 12/11/2022] Open
Abstract
BACKGROUND Adiponectin protein and some variations in its gene, ADIPOQ have recently been associated with cancer because they regulate glucose and lipid metabolism as well as anti-apoptotic and anti-inflammatory proteins. AIM The aim of this study was to analyse the relationship between selected biochemical markers, anthropometric indices and ADIPOQ rs2241766 and rs1501299 SNPs in ductal infiltrating breast cancer (DIBC) in a Mexican population. METHODS This cross-sectional study included 64 DIBC patients and 167 healthy women. Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis was performed to identify the genotypes of the rs2241766 (exon 2) and rs1501299 (intron 2) ADIPOQ polymorphisms. Corporal composition and biochemical markers included body mass index (BMI), waist circumference (WC), hip circumference (HC), waist-hip ratio (WHR), glucose, cholesterol, triglycerides and high- and low-density lipoprotein cholesterol. RESULTS Patients with DIBC had higher serum glucose, WC and WHR than controls. Intergroup differences in allele and genotype frequencies were found for both polymorphisms (P < 0.05). Patients carrying the rs2241766 TT and TG genotypes had higher values of WC, HC and WHR, but only TG carriers had higher levels of glucose. For the SNP rs1501299, carriers of the GG genotype in the DIBC group had higher values of glucose, WC, HC and WHR than the respective control group. CONCLUSIONS These results suggest that WC, HC and WHR are better predictors of DIBC than BMI. The ADIPOQ SNP rs2241766 emerges as a protective factor, whereas rs1501299 is a risk factor for DIBC development in a Mexican population.
Collapse
Affiliation(s)
- Nelly Margarita Macías-Gómez
- Departamento de Promoción, Preservación y Desarrollo de la Salud, Universidad de Guadalajara, Jalisco, México
- * E-mail:
| | | | | | - Evelia Leal-Ugarte
- Facultad de Medicina e Ingeniería en Sistemas Computacionales de Matamoros, Universidad Autónoma de Tamaulipas, Tamaulipas, México
| | | | - Jorge Peregrina-Sandoval
- Centro Universitario de Ciencias Biológicas y Agropecuarias, Universidad de Guadalajara, Jalisco, México
| |
Collapse
|
9
|
Falakian Z, Shahani T, Rezaie R, Mazloomzadeh S, Sirati F, Jalilvand A, Jahangiri F, Bahmani P, Jadali F, Atarian S, Eghdam-Zamir R, Biglari A. Patients With Invasive Ductal Carcinoma Have Reduced Levels of Decorin Expression in Their Breast Tissue Compared to Patients With Fibroadenoma While Plasma Decorin Remains Unchanged. Arch Iran Med 2018; 21:509-517. [PMID: 30551691] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Received: 01/15/2018] [Accepted: 10/07/2018] [Indexed: 06/09/2023]
Abstract
BACKGROUND Reduction in the level of tissue decorin is a hallmark of many types of cancer including breast carcinoma. However, reduced decorin expression has also been reported in several types of benign tumors to the extent that it has been proposed as a tissue marker to differentiate malignant from benign tumors. The aim of this study was to investigate the potential role of plasma decorin to distinguish breast cancer from fibroadenoma, the second most common type of benign tumor, after fibrocystic disease. METHODS From 35 patients recruited in this study, 24 were affected with invasive ductal carcinoma, either grade II (n = 14) or grade III (n = 10). The other 11 patients had fibroadenoma lesions in their breasts. Tissue decorin mRNA and protein levels were assessed with real-time qPCR and Immunohistochemical analysis. ELISA was employed to measure plasma levels of decorin. RESULTS The mean plasma decorin in cancer patients was measured to be 5.42 ± 1.83 ng/mL while fibroadenoma patients had an average of 4.22 ± 1.17 ng/mL decorin in their plasma. The difference was not significant. However, the mean expression level of decorin mRNA calculated by the 2-ΔΔCt method was 5.6-fold lower in the biopsied tissue specimens of IDC patients versus fibroadenoma, as expected. Consistent reduction in protein abundance was observed in the studied tissue sections. CONCLUSION We have shown that tissue decorin is a reliable marker, unaffected by patient disease stage, to differentiate IDC from fibroadenoma. However, plasma decorin does not seem to have diagnostic value in this regard.
Collapse
Affiliation(s)
- Zeinab Falakian
- Department of Genetics and Molecular Medicine, School of Medicine, Zanjan University of Medical Sciences (ZUMS), Zanjan, Iran
- Cancer Gene Therapy Research Center, Zanjan University of Medical Sciences (ZUMS), Zanjan, Iran
| | - Tina Shahani
- Department of Genetics and Molecular Medicine, School of Medicine, Zanjan University of Medical Sciences (ZUMS), Zanjan, Iran
- Cancer Gene Therapy Research Center, Zanjan University of Medical Sciences (ZUMS), Zanjan, Iran
| | - Razieh Rezaie
- Department of Genetics and Molecular Medicine, School of Medicine, Zanjan University of Medical Sciences (ZUMS), Zanjan, Iran
- Cancer Gene Therapy Research Center, Zanjan University of Medical Sciences (ZUMS), Zanjan, Iran
| | - Saeideh Mazloomzadeh
- Social Determinants of Health Research Center, Zanjan University of Medical Sciences (ZUMS), Zanjan, Iran
| | | | - Ahmad Jalilvand
- Department of Pathology, School of Medicine, Zanjan University of Medical Sciences (ZUMS), Zanjan, Iran
| | | | | | | | - Shahrokh Atarian
- Valiasr Hospital, Zanjan University of Medical Sciences (ZUMS), Zanjan, Iran
| | - Reza Eghdam-Zamir
- Radiation Oncology Department, Tabriz University of Medical Sciences (TUOMS), Tabriz, Iran
| | - Alireza Biglari
- Department of Genetics and Molecular Medicine, School of Medicine, Zanjan University of Medical Sciences (ZUMS), Zanjan, Iran
- Cancer Gene Therapy Research Center, Zanjan University of Medical Sciences (ZUMS), Zanjan, Iran
| |
Collapse
|
10
|
Linjawi S, AlGaithy Z, Sindi S, Hamdi N, Linjawi A, Alharbi M. Regulation of Lipocalin-2 oncogene and its impact on gene polymorphisms on breast cancer patients in Jeddah, Saudi Arabia. Saudi Med J 2018; 39:558-563. [PMID: 29915849 PMCID: PMC6058746 DOI: 10.15537/smj.2018.6.22950] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2018] [Accepted: 05/16/2018] [Indexed: 12/15/2022] Open
Abstract
OBJECTIVES To identify the impact of Lipocalin-2 (LCN2) gene polymorphisms on breast cancer patients in western Saudi Arabia. METHODS It is a case control study in which blood samples of participants from Medical Reference Clinics and King Abdulaziz University Hospital in Jeddah, Saudi Arabia have been taken between 2014 and 2016. This study recruited 128 participants (50% control, 50% patients) and used Tetra-Primer amplification-refractory mutation system-polymerase chain reaction method for the detection of missense SNP (rs11556770). The study measured LCN2 plasma protein expression by enzyme-linked immunosorbent assay technique. Results: The results have shown that 100% of the genotypes were normal allele (G/G). In contrast, the plasma level of LCN2 was considerably elevated among patients as compared to control (p=0.001), and higher in invasive ductal carcinoma patients (p=0.001). The LCN2 protein expression in plasma level was significantly elevated among patients, particularly who demonstrated invasive ductal carcinoma. Conclusion: There is no significant relationship between breast cancer patients and LCN2 gene polymorphisms (rs11556770).
Collapse
Affiliation(s)
- Sabah Linjawi
- Biology Department, Faculty of Science, Faculty of Medicine, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia. E-mail.
| | | | | | | | | | | |
Collapse
|
11
|
Kankava K, Kvaratskhelia E, Burkadze G, Kokhreidze I, Gogokhia N, Abzianidze E. LINE-1 METHYLATION IN BLOOD AND TISSUES OF PATIENTS WITH BREAST CANCER. Georgian Med News 2018:107-112. [PMID: 29697392] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Abstract
Methylation is an epigenetic alteration proved to be involved in many disease processes including cancer. This change affects mainly gene promoters and repetitive sequences in genome. Long Interspersed Nuclear Element-1 (LINE-1) is a family of retrotransposons - repetitive elements that modify gene activity and can themselves be targeted by epigenetic mechanisms. LINE-1 methylation level is a surrogate marker for global methylation. In many conditions this parameter is found to be altered not only in affected cell groups, but also throughout other tissues. The aim of our study was to compare LINE-1 methylation pattern in DNA extracted from blood of the patients with benign and malignant breast tissue. In addition, we investigated correlation of LINE-1 methylation in blood and tissues of same patients and relationship of all variables with histopathologic and phenotypic characteristics of tumors. Patients with biopsy-proved ductal invasive carcinoma of breast and no preoperative chemo/radiotherapy were chosen for the study group. Another pool of patients with various benign breast lesions represented controls. Blood samples from both group members were collected preoperatively. Tumor tissue sections were processed for pathology report and part of remaining tissue was used for methylation study. LINE-1 methylation level was quantified using ELISA-based assay. It was analyzed in combination with histologic and phenotypic tumor parameters and compared between different tissues and different study groups. LINE-1 was found to be significantly hypomethylated in breast cancer tissue compared to blood. Blood samples of patients with malignant tumors showed slightly lower methylation level, than samples obtained from control group members. Lymphovascular invasion was the only aggressiveness-determining factor that was found to be at least weakly correlated with LINE-1 hypomethylation in blood. We can conclude, that global hypomethylation measured by LINE-1 methylation level is significant in tumor tissue. But there is no significant difference between LINE-1 methylation levels in blood of patients with benign and malignant breast tumors; therefor LINE-1 hypomethylation in blood cannot be used as a marker for early tumor detection. Neither is it valid for determination of tumor behavior.
Collapse
Affiliation(s)
- K Kankava
- Tbilisi State Medical University, Department of Molecular and Medical Genetics; Department of Molecular Pathology; The First University Clinic; Department of Laboratory Medicine, Georgia
| | - E Kvaratskhelia
- Tbilisi State Medical University, Department of Molecular and Medical Genetics; Department of Molecular Pathology; The First University Clinic; Department of Laboratory Medicine, Georgia
| | - G Burkadze
- Tbilisi State Medical University, Department of Molecular and Medical Genetics; Department of Molecular Pathology; The First University Clinic; Department of Laboratory Medicine, Georgia
| | - I Kokhreidze
- Tbilisi State Medical University, Department of Molecular and Medical Genetics; Department of Molecular Pathology; The First University Clinic; Department of Laboratory Medicine, Georgia
| | - N Gogokhia
- Tbilisi State Medical University, Department of Molecular and Medical Genetics; Department of Molecular Pathology; The First University Clinic; Department of Laboratory Medicine, Georgia
| | - E Abzianidze
- Tbilisi State Medical University, Department of Molecular and Medical Genetics; Department of Molecular Pathology; The First University Clinic; Department of Laboratory Medicine, Georgia
| |
Collapse
|
12
|
Cala MP, Aldana J, Medina J, Sánchez J, Guio J, Wist J, Meesters RJW. Multiplatform plasma metabolic and lipid fingerprinting of breast cancer: A pilot control-case study in Colombian Hispanic women. PLoS One 2018; 13:e0190958. [PMID: 29438405 PMCID: PMC5810980 DOI: 10.1371/journal.pone.0190958] [Citation(s) in RCA: 40] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2017] [Accepted: 12/22/2017] [Indexed: 01/22/2023] Open
Abstract
Breast cancer (BC) is a highly heterogeneous disease associated with metabolic reprogramming. The shifts in the metabolome caused by BC still lack data from Latin populations of Hispanic origin. In this pilot study, metabolomic and lipidomic approaches were performed to establish a plasma metabolic fingerprint of Colombian Hispanic women with BC. Data from 1H-NMR, GC-MS and LC-MS were combined and compared. Statistics showed discrimination between breast cancer and healthy subjects on all analytical platforms. The differentiating metabolites were involved in glycerolipid, glycerophospholipid, amino acid and fatty acid metabolism. This study demonstrates the usefulness of multiplatform approaches in metabolic/lipid fingerprinting studies to broaden the outlook of possible shifts in metabolism. Our findings propose relevant plasma metabolites that could contribute to a better understanding of underlying metabolic shifts driven by BC in women of Colombian Hispanic origin. Particularly, the understanding of the up-regulation of long chain fatty acyl carnitines and the down-regulation of cyclic phosphatidic acid (cPA). In addition, the mapped metabolic signatures in breast cancer were similar but not identical to those reported for non-Hispanic women, despite racial differences.
Collapse
Affiliation(s)
- Mónica P. Cala
- Department of Chemistry, Grupo de Investigación en Química Analítica y Bioanalítica (GABIO), Universidad de los Andes, Bogotá D.C., Colombia
| | - Julian Aldana
- Department of Chemistry, Grupo de Investigación en Química Analítica y Bioanalítica (GABIO), Universidad de los Andes, Bogotá D.C., Colombia
| | - Jessica Medina
- Department of Chemistry, Universidad del Valle, Cali, Colombia
| | - Julián Sánchez
- Liga contra el Cáncer Seccional Bogotá, Bogotá, Colombia
| | - José Guio
- Liga contra el Cáncer Seccional Bogotá, Bogotá, Colombia
| | - Julien Wist
- Department of Chemistry, Universidad del Valle, Cali, Colombia
| | - Roland J. W. Meesters
- Department of Chemistry, Grupo de Investigación en Química Analítica y Bioanalítica (GABIO), Universidad de los Andes, Bogotá D.C., Colombia
| |
Collapse
|
13
|
Beinse G, Berger F, Cottu P, Dujaric ME, Kriegel I, Guilhaume MN, Diéras V, Cabel L, Pierga JY, Bidard FC. Circulating tumor cell count and thrombosis in metastatic breast cancer. J Thromb Haemost 2017; 15:1981-1988. [PMID: 28779538 DOI: 10.1111/jth.13792] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2016] [Indexed: 11/28/2022]
Abstract
Essentials Tumor cells circulating in blood (CTC) may favor thrombotic events in cancer patients. We assessed the impact of CTC on the risk of thrombosis in metastatic breast cancer. Baseline CTC detection was the only independent factor associated with the risk of thrombosis. CTC detection under therapy may be the hidden link between tumor progression & thrombosis. SUMMARY Background Circulating tumor cell (CTC) count is a major prognostic factor in metastatic breast cancer (MBC) and has been reported to be associated with thrombosis in short-term studies on MBC patients. Objective To assess whether CTC detection (CellSearch® ) before first-line chemotherapy impacts the risk of thrombosis throughout the course of MBC. Patients/Methods Among patients included before first-line chemotherapy for MBC in the prospective IC2006-04 CTC detection study (NCT00898014), the electronic medical files of those patients treated at Institut Curie (Paris, France) were searched in silico and manually checked for incident venous or arterial thrombotic events (TE) in the course of MBC. Univariate and multivariate analyses were performed using Cox and Fine-Gray models, adjusted for age and Khorana score. Results/Conclusions With a median follow-up of 64 months (25-81 months), among the 142 patients included, 34 (24%) experienced a TE (incidence rate, 8 TE/100 patient-years). The TE incidence rate was 13 TE/100 patient-years for the 80 patients with ≥ 1 CTC/7.5 mL of blood before initiating first-line chemotherapy, vs. only 4 TE/100 patient-years for the 62 CTC-negative patients. Fine-Gray multivariate analysis (with death as competing event) included age, Khorana score and baseline lactate dehydrogenase and CTC levels: detectable CTC was the only factor significantly associated with an increased risk of TE (sub-distribution hazard ratio [SHR] for patients with [1-4] CTC = 3.1, 95% CI [1.1; 8.6], SHR for patients with ≥ 5 CTC = 1.4, 95% CI [0.5; 4.6]). This study shows that CTC detection before starting first-line chemotherapy is an independent risk factor for TE in MBC patients.
Collapse
Affiliation(s)
- G Beinse
- Department of Medical Oncology, Institut Curie, PSL Research University, Paris, France
| | - F Berger
- Institut Curie, Unit of Biometry, PSL Research University, INSERM U900, Paris, France
| | - P Cottu
- Department of Medical Oncology, Institut Curie, PSL Research University, Paris, France
| | - M-E Dujaric
- Institut Curie, Unit of Biometry, PSL Research University, INSERM U900, Paris, France
| | - I Kriegel
- Department of Anesthesiology, Institut Curie, PSL Research University, Paris, France
| | - M-N Guilhaume
- Department of Medical Oncology, Institut Curie, PSL Research University, Paris, France
| | - V Diéras
- Department of Medical Oncology, Institut Curie, PSL Research University, Paris, France
| | - L Cabel
- Department of Medical Oncology, Institut Curie, PSL Research University, Paris, France
| | - J-Y Pierga
- Department of Medical Oncology, Institut Curie, PSL Research University, Paris, France
- Université Paris Descartes, Paris, France
| | - F-C Bidard
- Department of Medical Oncology, Institut Curie, PSL Research University, Paris, France
| |
Collapse
|
14
|
Usmani A, Shoro AA, Shirazi B, Memon Z, Hussain M. MiR-16: A novel hereditary marker in breast cancer and their offspring. J PAK MED ASSOC 2017; 67:446-450. [PMID: 28303998] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
OBJECTIVE To analyse micro ribonucleic acid-16 in sera of invasive intraductal breast carcinoma in stage III and compare its expression in their daughters and healthy women. METHODS The study took place from January 2013 till December 2015. This case-control study was conducted at the Ziauddin Cancer Hospital, Karachi, and comprised breast cancer patients and healthy individuals. Stage III invasive intraductal breast cancer patients (cases), their age-matched healthy individuals (control group A) and patients' daughters (control group B) were included. Subjects with stage I cancer and their daughters and subjects with stage IV and their daughters were also included. Serum tests were run on real-time quantitative reverse transcription polymerase chain reaction. Threshold cycle was determined and fold change was calculated. Fold change was applied between the groups. SPSS 20 was used for data analysis. RESULTS Of the 194 participants, there were 50(25.8%) cases, 50(25.8%) group A controls, 35(18%) group B controls, 20(10.3%) stage I patients, 11(5.7%) daughters of stage 1 patients, 20(10.3%) patients of stage IV and 8(4.1%) daughters of stage IV patients. Micro ribonucleic acid-16 was higher in cases than controls (p=0.001). Group B showed significant gene expression than group A (p=0.001). Stage IV patients and daughters showed expression of micro ribonucleic acid-16 (p=0.001). Triple negative receptor cases showed a greater expression of gene (p=0.001). CONCLUSIONS Micro ribonucleic acid-16 can be used as a prognostic, diagnostic as well as a predictive marker in breast cancer patients and their offspring.
Collapse
MESH Headings
- Adolescent
- Adult
- Biomarkers, Tumor/blood
- Biomarkers, Tumor/genetics
- Breast Neoplasms/blood
- Breast Neoplasms/diagnosis
- Breast Neoplasms/epidemiology
- Breast Neoplasms/genetics
- Carcinoma, Ductal, Breast/blood
- Carcinoma, Ductal, Breast/diagnosis
- Carcinoma, Ductal, Breast/epidemiology
- Carcinoma, Ductal, Breast/genetics
- Case-Control Studies
- Female
- Humans
- MicroRNAs/blood
- Middle Aged
- Young Adult
Collapse
|
15
|
Liu M, Xing LQ, Liu YJ. A three-long noncoding RNA signature as a diagnostic biomarker for differentiating between triple-negative and non-triple-negative breast cancers. Medicine (Baltimore) 2017; 96:e6222. [PMID: 28248879 PMCID: PMC5340452 DOI: 10.1097/md.0000000000006222] [Citation(s) in RCA: 48] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
BACKGROUND Triple-negative breast cancer (TNBC) is an aggressive cancer with unfavorable outcome and it is useful to explore noninvasive biomarkers for its early diagnosis. Here, we identified differentially expressed long noncoding RNAs (lncRNAs) in blood samples of patients with TNBC to assess their diagnostic value. METHODS Differential expression of lncRNAs in plasma of patients with TNBC (n = 25) and non-TNBC (NTNBC; n = 35) and in healthy controls was compared by microarray analysis and validated by real-time PCR. lncRNA expression between plasma and BC tissues was compared using Pearson correlation test. Logit model was used to obtain a new lncRNA-based score. Receiver operating characteristic analysis was performed to assess the diagnostic value of the selected lncRNAs. RESULTS Microarray data showed that 41 lncRNAs were aberrantly expressed. Among these, antisense noncoding RNA in the INK4 locus (ANRIL), hypoxia inducible factor 1alpha antisense RNA-2 (HIF1A-AS2), and urothelial carcinoma-associated 1 (UCA1) were markedly upregulated in plasma of patients with TNBC compared with patients with NTNBC (P < 0.01). HIF1A-AS2 expression was positively associated with its tissue levels (r = 0.670, P < 0.01). AUC (95% CI) of ANRIL, HIF1A-AS2, and UCA1 was 0.785 (0.660-0.881), 0.739 (0.610-0.844), and 0.817 (0.696-0.905), respectively. TNBCSigLnc-3, a new score obtained using the logit model, showed excellent diagnostic performance, with AUC of 0.934 (0.839-0.982), sensitivity of 76.0%, and specificity of 97.1%. CONCLUSION ANRIL, HIF1A-AS2, and UCA1 expression was significantly increased in plasma of patients with TNBC, suggesting their use as TNBC-specific diagnostic biomarkers.
Collapse
|
16
|
Dai H, Gallagher D, Schmitt S, Pessetto ZY, Fan F, Godwin AK, Tawfik O. Role of miR-139 as a surrogate marker for tumor aggression in breast cancer. Hum Pathol 2016; 61:68-77. [PMID: 27864119 DOI: 10.1016/j.humpath.2016.11.001] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/22/2016] [Revised: 11/01/2016] [Accepted: 11/03/2016] [Indexed: 02/07/2023]
Abstract
MicroRNAs are non-protein coding molecules that play a key role in oncogenesis, tumor progression, and metastasis in many types of malignancies including breast cancer. In the current study, we studied the expression of microRNA-139-5p (miR-139) in invasive ductal carcinoma (IDC) of the breast and correlated its expression with tumor grade, molecular subtype, hormonal status, human epidermal growth factor receptor 2 status, proliferation index, tumor size, lymph node status, patient's age, and overall survival in 74 IDC cases. In addition, we compared and correlated miR-139 expression in 18 paired serum and tissue samples from patients with IDC to assess its value as a serum marker. Our data showed that miR-139 was down-regulated in all tumor tissue samples compared with control. More pronounced down-regulation was seen in tumors that were higher grade, estrogen receptor negative, progesterone receptor negative, more proliferative, or larger in size (P < .05). Although not statistically significant, lower miR-139 level was frequently associated with human epidermal growth factor receptor 2 overexpression. In addition, significantly lower miR-139 tissue level was seen in patients who were deceased (P = .027), although older age (>50 years) and positive local nodal disease did not adversely affect miR-139 expression. In contrast, serum miR-139 profile of the patients appeared similar to that of normal control. In conclusion, our study demonstrated that down-regulation of miR-139 was associated with aggressive tumor behavior and disease progression in breast cancer. miR-139 may serve as a risk assessment biomarker in tailoring treatment options.
Collapse
MESH Headings
- Biomarkers, Tumor/classification
- Biomarkers, Tumor/genetics
- Biopsy
- Breast Neoplasms/blood
- Breast Neoplasms/genetics
- Breast Neoplasms/mortality
- Breast Neoplasms/pathology
- Carcinoma, Ductal, Breast/blood
- Carcinoma, Ductal, Breast/genetics
- Carcinoma, Ductal, Breast/mortality
- Carcinoma, Ductal, Breast/pathology
- Cell Proliferation
- Disease Progression
- Down-Regulation
- Female
- Gene Expression Regulation, Neoplastic
- Genetic Predisposition to Disease
- Humans
- MicroRNAs/blood
- MicroRNAs/genetics
- Middle Aged
- Neoplasm Grading
- Neoplasm Invasiveness
- Phenotype
- Retrospective Studies
- Reverse Transcriptase Polymerase Chain Reaction
- Risk Factors
- Survival Analysis
- Tumor Burden
Collapse
Affiliation(s)
- Hongyan Dai
- Department of Pathology and Laboratory Medicine, The University of Kansas Medical Center, Kansas City, KS 66160
| | - Dan Gallagher
- Department of Pathology and Laboratory Medicine, The University of Kansas Medical Center, Kansas City, KS 66160
| | - Sarah Schmitt
- Department of Pathology and Laboratory Medicine, The University of Kansas Medical Center, Kansas City, KS 66160
| | - Ziyan Y Pessetto
- Department of Pathology and Laboratory Medicine, The University of Kansas Medical Center, Kansas City, KS 66160
| | - Fang Fan
- Department of Pathology and Laboratory Medicine, The University of Kansas Medical Center, Kansas City, KS 66160
| | - Andrew K Godwin
- Department of Pathology and Laboratory Medicine, The University of Kansas Medical Center, Kansas City, KS 66160
| | - Ossama Tawfik
- Department of Pathology and Laboratory Medicine, The University of Kansas Medical Center, Kansas City, KS 66160.
| |
Collapse
|
17
|
Dyachenko L, Havrysh K, Lytovchenko A, Dosenko I, Antoniuk S, Filonenko V, Kiyamova R. Autoantibody Response to ZRF1 and KRR1 SEREX Antigens in Patients with Breast Tumors of Different Histological Types and Grades. Dis Markers 2016; 2016:5128720. [PMID: 27847402 PMCID: PMC5099469 DOI: 10.1155/2016/5128720] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/20/2016] [Revised: 08/30/2016] [Accepted: 09/29/2016] [Indexed: 12/13/2022]
Abstract
Purpose. To investigate a frequency of antibody response to SEREX-identified medullary breast carcinoma autoantigens ZRF1 and KRR1 in sera of breast cancer patients taking into account clinical and molecular characteristics of tumors for opening of new perspectives in creation of minimally invasive immunological tests for cancer diagnostics. Methods. Enzyme-linked immunosorbent assay and bioinformatics analysis. Results. Increased frequency of antibody response was found in sera of breast cancer patients to ZRF and KRR1 antigens. The antibody response to these antigens was higher in sera of patients with invasive ductal carcinoma than in sera of patients with other histological types of breast tumors. Moreover, more frequent antibody response to ZRF antigen was found in sera of patients with less aggressive tumors. The sequence analysis of ZRF1 antigen SEREX clones obtained from cDNA libraries of different tumors demonstrates that they encode different protein isoforms. Conclusion. Tumor-associated antigens KRR1 and ZRF1 and their cognate autoantibodies could be considered as potential molecular markers of breast cancer which need to be further investigated.
Collapse
MESH Headings
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Antigens, Neoplasm/blood
- Antigens, Neoplasm/genetics
- Antigens, Neoplasm/immunology
- Autoantibodies/blood
- Base Sequence
- Biomarkers, Tumor/blood
- Biomarkers, Tumor/immunology
- Breast Neoplasms/blood
- Breast Neoplasms/immunology
- Breast Neoplasms/pathology
- Carcinoma, Ductal, Breast/blood
- Carcinoma, Ductal, Breast/immunology
- Carcinoma, Ductal, Breast/pathology
- Carcinoma, Lobular/blood
- Carcinoma, Lobular/immunology
- Carcinoma, Lobular/pathology
- Carcinoma, Medullary/blood
- Carcinoma, Medullary/immunology
- Carcinoma, Medullary/pathology
- Case-Control Studies
- DNA-Binding Proteins/blood
- DNA-Binding Proteins/genetics
- DNA-Binding Proteins/immunology
- Enzyme-Linked Immunosorbent Assay
- Female
- Follow-Up Studies
- Gene Library
- Humans
- Middle Aged
- Molecular Chaperones
- Neoplasm Grading
- Neoplasm Staging
- Nuclear Pore Complex Proteins/blood
- Nuclear Pore Complex Proteins/genetics
- Nuclear Pore Complex Proteins/immunology
- Oncogene Proteins/blood
- Oncogene Proteins/genetics
- Oncogene Proteins/immunology
- Prognosis
- RNA-Binding Proteins/blood
- RNA-Binding Proteins/genetics
- RNA-Binding Proteins/immunology
- Young Adult
Collapse
Affiliation(s)
- Lada Dyachenko
- Department of Cell Signaling, Institute of Molecular Biology and Genetics NASU, Kyiv, Ukraine
| | - Kristina Havrysh
- Institute of Fundamental Medicine and Biology, Kazan Federal University, Kazan, Russia
| | - Anita Lytovchenko
- Department of Cell Signaling, Institute of Molecular Biology and Genetics NASU, Kyiv, Ukraine
| | - Irina Dosenko
- Breast Cancer Department, National Cancer Institute, Kyiv, Ukraine
| | - Stepan Antoniuk
- Department of Oncological Pathology, Dnipropetrovsk Regional Center of Pathology, Dnipropetrovsk, Ukraine
| | - Valeriy Filonenko
- Department of Cell Signaling, Institute of Molecular Biology and Genetics NASU, Kyiv, Ukraine
| | - Ramziya Kiyamova
- Department of Cell Signaling, Institute of Molecular Biology and Genetics NASU, Kyiv, Ukraine
- Institute of Fundamental Medicine and Biology, Kazan Federal University, Kazan, Russia
| |
Collapse
|
18
|
Kankava K, Kvaratskhelia E, Abzianidze E. A STUDY OF THE RELATIONSHIP BETWEEN LEVELS OF METHYLTRANSFERASES IN PERIPHERAL BLOOD MONONUCLEAR CELLS AND CHARACTERISTICS OF TUMOR IN PATIENTS WITH DUCTAL INVASIVE CARCINOMA OF BREAST. Georgian Med News 2016:31-35. [PMID: 27845283] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
The role of epigenetics in tumor development and progression is actively being studied. The aim of our current pilot study is to analyze correlation of changes in the levels of methyltransferases in nuclear extracts of blood cells with some morphological and phenotypic characteristics of breast cancer. The levels of DNMT1, DNMT3a and H3K4 methyltransferase were measured. The results showed that the level of DNMT1 was highest in the control group but correlation with the tumor grade was just moderate. DNMT3a was found in highest level in Grade III cancer group, followed by Grade II and Grade I groups. Correlation of DNMT1 level with tumor grade was moderate. An opposite pattern was seen for H3K4 methyltransferase. DNMT3a level was higher in larger tumors, while the level of H3K4 methyltransferase was lowest in large tumors with significant negative correlation with the tumor size. This primary study shows that there are some changes in methyltransferase levels in PBMC from breast cancer patients. These changes are most probably attributed to modification of initiation as well as sustainment of methylated status of products.
Collapse
Affiliation(s)
- K Kankava
- Tbilisi State Medical University, Department of Molecular and Medical Genetics, Georgia
| | - E Kvaratskhelia
- Tbilisi State Medical University, Department of Molecular and Medical Genetics, Georgia
| | - E Abzianidze
- Tbilisi State Medical University, Department of Molecular and Medical Genetics, Georgia
| |
Collapse
|
19
|
Karlikova M, Topolcan O, Narsanska A, Kucera R, Treskova I, Treska V. Circulating Growth and Angiogenic Factors and Lymph Node Status in Early-stage Breast Cancer - A Pilot Study. Anticancer Res 2016; 36:4209-4214. [PMID: 27466533] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2016] [Accepted: 06/16/2016] [Indexed: 06/06/2023]
Abstract
AIM To evaluate the possibility of selected biomarkers for breast cancer diagnostics and/or treatment monitoring, lymph node (LN) status determination and clinical decision regarding axillary node dissection. PATIENTS AND METHODS Two hundred and eleven patients with malignant breast cancer and 42 age-matched healthy controls were enrolled. Serum insulin-like growth factor 1 (IGF1) and insulin-like growth factor binding protein 3 (IGFBP3) and plasma epidermal growth factor (EGF), vascular endothelial growth factor (VEGF), osteoprotegerin (OPG) and osteopontin (OPN) were measured. We compared patients versus controls, patients with negative versus positive lymph node and patients with and without axillary lymph node dissection (ALND). RESULTS We found elevated IGF1 and VEGF levels in patients with lymph node metastases compared to controls (p=0.0179 and p=0.0091, respectively) and in patients with ALND (p=0.0337 and p=0.0438, respectively). CONCLUSION Circulating IGF1 and VEGF levels may predict the presence of lymph node metastases and help in the decision to avoid ALND in patients with early-stage breast cancer.
Collapse
Affiliation(s)
- Marie Karlikova
- Laboratory of Immunoanalysis, Faculty Hospital in Pilsen and Faculty of Medicine in Pilsen, Charles University in Prague, Prague, Czech Republic
| | - Ondrej Topolcan
- Laboratory of Immunoanalysis, Faculty Hospital in Pilsen and Faculty of Medicine in Pilsen, Charles University in Prague, Prague, Czech Republic
| | - Andrea Narsanska
- Department of Surgery, Faculty Hospital in Pilsen, Faculty of Medicine in Pilsen, Charles University in Prague, Prague, Czech Republic
| | - Radek Kucera
- Laboratory of Immunoanalysis, Faculty Hospital in Pilsen and Faculty of Medicine in Pilsen, Charles University in Prague, Prague, Czech Republic
| | - Inka Treskova
- Department of Surgery, Faculty Hospital in Pilsen, Faculty of Medicine in Pilsen, Charles University in Prague, Prague, Czech Republic
| | - Vladislav Treska
- Department of Surgery, Faculty Hospital in Pilsen, Faculty of Medicine in Pilsen, Charles University in Prague, Prague, Czech Republic
| |
Collapse
|
20
|
Kamel AM, Teama S, Fawzy A, El Deftar M. Plasma DNA integrity index as a potential molecular diagnostic marker for breast cancer. Tumour Biol 2016; 37:7565-72. [PMID: 26684805 DOI: 10.1007/s13277-015-4624-3] [Citation(s) in RCA: 36] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2015] [Accepted: 12/10/2015] [Indexed: 12/11/2022] Open
Abstract
Plasma DNA integrity index is increased in various malignancies including breast cancer, the most common cancer in women worldwide; early detection is crucial for successful treatment. Current screening methods fail to detect many cases of breast cancer at an early stage. In this study, we evaluated the level of plasma DNA integrity index in 260 females (95 with breast cancer, 95 with benign breast lesions, and 70 healthy controls) to verify its potential value in discriminating malignant from benign breast lesions. The criteria of the American Joint Committee on Cancer were used for staging of breast cancer patients. DNA integrity index was measured by real-time PCR. DNA integrity index was significantly higher in breast cancer than in benign breast patients and healthy subjects (P = <0.001). DNA integrity index is correlated with TNM stage. Given 100 % specificity, the highest sensitivity achieved in detecting cancer group was 85.3 % at 0.55 DNA integrity index cutoff. In conclusion, the plasma DNA integrity index may be a promising molecular diagnostic marker of malignancy in breast lesions.
Collapse
MESH Headings
- Adult
- Aged
- Biomarkers, Tumor/blood
- Biomarkers, Tumor/genetics
- Breast/metabolism
- Breast/pathology
- Breast Neoplasms/blood
- Breast Neoplasms/diagnosis
- Breast Neoplasms/genetics
- Carcinoma, Ductal, Breast/blood
- Carcinoma, Ductal, Breast/diagnosis
- Carcinoma, Ductal, Breast/genetics
- Carcinoma, Lobular/blood
- Carcinoma, Lobular/diagnosis
- Carcinoma, Lobular/genetics
- Case-Control Studies
- DNA, Neoplasm/blood
- DNA, Neoplasm/genetics
- Female
- Follow-Up Studies
- Humans
- Middle Aged
- Neoplasm Grading
- Neoplasm Staging
- Plasma/chemistry
- Prognosis
- ROC Curve
- Real-Time Polymerase Chain Reaction
Collapse
Affiliation(s)
- Azza M Kamel
- Department of Clinical Pathology, National Cancer Institute, Cairo University, Fom El-Khalig Square, Kasr El-Aini Street, 11796, Cairo, Egypt.
| | - Salwa Teama
- Medical Research Center, Molecular Biology Unit, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
| | - Amal Fawzy
- Department of Clinical Pathology, National Cancer Institute, Cairo University, Fom El-Khalig Square, Kasr El-Aini Street, 11796, Cairo, Egypt
| | - Mervat El Deftar
- Department of Pathology, Tissue culture & Cytogenetic unit, National Cancer Institute, Cairo University, Cairo, Egypt
| |
Collapse
|
21
|
Cecene G, Ak S, Eskiler GG, Demirdogen E, Erturk E, Gokgoz S, Polatkan V, Egeli U, Tunca B, Tezcan G, Topal U, Tolunay S, Tasdelen I. Circulating miR-195 as a Therapeutic Biomarker in Turkish Breast Cancer Patients. Asian Pac J Cancer Prev 2016; 17:4241-4246. [PMID: 27797225] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/06/2023] Open
Abstract
BACKGROUND Dysregulation of miRNA expression may be used as a biomarker for specific tumours because it may contribute to development of cancer. Circulating miRNA profiles have been highlighted for their potential as predictive markers in heterogeneous diseases such as breast cancer. In the literature, there is evidence that miR-195 levels are differentially expressed pre- and post-operative periods in breast cancer patients. At the same time, miRNA expression levels may vary because of ethnic origins. This study aimed to determine expression levels and potential roles of miR-195 in Turkish breast cancer patients. MATERIALS AND METHODS The expression patterns of miR-195 were initially examined in breast cancer tissues (luminal A and B type) (n=96). Subsequently, blood samples were prospectively collected from preoperative and postoperative Turkish breast cancer patients and disease free controls. Total RNA was isolated, and the expression level of miR-195 was quantified by real-time PCR. RESULTS We found that miR-195 level was altered in Turkish breast cancer patients, with down-regulation evident in breast cancer tissues compared to normal adjacent specimens. Furthermore, circulating levels of miR- 195 was significantly decreased in post-operative blood samples compared with pre-operative levels (p=0.01 and <0.05). However, miR-195 was significantly increased in pre-operative blood samples of the luminal B type (p= 0.04 and <0.05). CONCLUSIONS This study represents the first report of a miR-195 expression profile in Turkish breast cancer patients. Our data suggests that miR-195 levels might be a clinically useful biomarker in the earliest stage of Turkish breast cancer patients.
Collapse
MESH Headings
- Adult
- Aged
- Biomarkers, Tumor/blood
- Biomarkers, Tumor/genetics
- Breast Neoplasms/blood
- Breast Neoplasms/pathology
- Breast Neoplasms/surgery
- Carcinoma, Ductal, Breast/blood
- Carcinoma, Ductal, Breast/secondary
- Carcinoma, Ductal, Breast/surgery
- Carcinoma, Lobular/blood
- Carcinoma, Lobular/secondary
- Carcinoma, Lobular/surgery
- Case-Control Studies
- Female
- Follow-Up Studies
- Gene Expression Profiling
- Gene Expression Regulation, Neoplastic
- Humans
- Lymphatic Metastasis
- MicroRNAs/blood
- MicroRNAs/genetics
- Middle Aged
- Neoplasm Invasiveness
- Neoplasm Staging
- Oligonucleotide Array Sequence Analysis
- Prognosis
- Real-Time Polymerase Chain Reaction
- Turkey
- Young Adult
Collapse
Affiliation(s)
- Gulsah Cecene
- Department of Medical Biology, Medical Faculty, Uludag University, Turkey E-mail :
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Yang JZ, Wang ZX, Ma LH, Shen XB, Sun Y, Hu DW, Sun LX. The organochlorine pesticides residues in the invasive ductal breast cancer patients. Environ Toxicol Pharmacol 2015; 40:698-703. [PMID: 26410088 DOI: 10.1016/j.etap.2015.07.007] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/03/2015] [Revised: 07/02/2015] [Accepted: 07/08/2015] [Indexed: 06/05/2023]
Abstract
Investigation of organochlorine pesticides residues (important environmental contamination causing malignant transformation) in breast cancer patients is valuable to understanding their roles in breast cancer. 75 invasive ductal carcinoma (IDC) patients were enrolled with control of 79 benign breast diseases patients and control of 80 healthy women. Morning fasting blood specimens and adipose tissue specimens beside the primary lesion were detected with gas chromatograph. In blood specimens, both levels of β-HCH and PCTA were higher in IDC than those in both controls (both p<0.05), and increasingly higher among the three IDC degrees. In adipose tissue specimens, all levels of β-HCH, PCTA and pp'-DDE were higher in IDC than those in control (all p<0.05) and increasingly higher among three IDC degrees. The levels of β-HCH, PCTA in both blood specimens and adipose tissue specimens were higher in estrogen receptor (ER) positive IDC than those in ER negative IDC (all p<0.05). The higher level of organochlorine pesticides residues in blood and adipose tissue specimens of IDC infers its association with IDC, but the details remains to reveal, and this study may helpful in this field.
Collapse
Affiliation(s)
- Jing-Zhe Yang
- The Affiliated Hospital of Chengde Medical College, 36 Nanyingzi Street, Chengde 067000, Hebei, China
| | - Zhu-Xin Wang
- The Affiliated Hospital of Chengde Medical College, 36 Nanyingzi Street, Chengde 067000, Hebei, China
| | - Li-Hui Ma
- The Affiliated Hospital of Chengde Medical College, 36 Nanyingzi Street, Chengde 067000, Hebei, China
| | - Xing-Bin Shen
- The Affiliated Hospital of Chengde Medical College, 36 Nanyingzi Street, Chengde 067000, Hebei, China
| | - Yu Sun
- The Affiliated Hospital of Chengde Medical College, 36 Nanyingzi Street, Chengde 067000, Hebei, China
| | - Da-Wei Hu
- The Affiliated Hospital of Chengde Medical College, 36 Nanyingzi Street, Chengde 067000, Hebei, China.
| | - Li-Xin Sun
- The Affiliated Hospital of Chengde Medical College, 36 Nanyingzi Street, Chengde 067000, Hebei, China.
| |
Collapse
|
23
|
Caglar M, Kupik O, Karabulut E, Høilund-Carlsen PF. Detection of bone metastases in breast cancer patients in the PET/CT era: Do we still need the bone scan? Rev Esp Med Nucl Imagen Mol 2015; 35:3-11. [PMID: 26514321 DOI: 10.1016/j.remn.2015.08.006] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2015] [Revised: 08/17/2015] [Accepted: 08/30/2015] [Indexed: 11/18/2022]
Abstract
AIM To examine the value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) for the detection of bone metastasis in breast cancer patients and assess whether whole body bone scan (BS) with (99m)Tc-methylene diphosphonate provides any additional information. MATERIAL AND METHODS Study group comprised 150 patients, mean age 52 years (range 27-85) with breast cancer, suspected of having bone metastases. All patients had undergone both FDG-PET/CT and BS with or without single photon emission tomography/computed tomography (SPECT/CT) within a period of 6 weeks. The final diagnosis of bone metastasis was established by histopathological findings, additional imaging, or clinical follow-up longer than 10 months. Cancer antigen 15-3 (CA15-3) and carcinoembryogenic antigen (CEA) were measured in all patients. RESULTS Histologically 83%, 7% and 10% had infiltrating ductal, lobular and mixed carcinoma respectively. Confirmed bone metastases were present in 86 patients (57.3%) and absent in 64 (42.7%). Mean CA15-3 and CEA values in patients with bone metastases were 74.6ng/mL and 60.4U/mL respectively, compared to 21.3ng/mL and 3.2U/mL without metastases (p<0.001). The sensitivity of FDG-PET/CT for the detection of bone metastases was 97.6% compared to 89.5% with SPECT/CT. In 57 patients, FDG-PET/CT correctly identified additional pulmonary, hepatic, nodal and other soft tissue metastases, not detected by BS. CONCLUSION Our findings suggest that FDG-PET/CT is superior to BS with or without SPECT/CT.
Collapse
MESH Headings
- Adult
- Aged
- Aged, 80 and over
- Biomarkers, Tumor/blood
- Bone Neoplasms/blood
- Bone Neoplasms/diagnostic imaging
- Bone Neoplasms/secondary
- Breast Neoplasms/pathology
- Carcinoembryonic Antigen/blood
- Carcinoma, Ductal, Breast/blood
- Carcinoma, Ductal, Breast/diagnostic imaging
- Carcinoma, Ductal, Breast/secondary
- Carcinoma, Lobular/blood
- Carcinoma, Lobular/diagnostic imaging
- Carcinoma, Lobular/secondary
- Female
- Fluorine Radioisotopes/analysis
- Fluorodeoxyglucose F18/analysis
- Humans
- Middle Aged
- Mucin-1/blood
- Positron Emission Tomography Computed Tomography
- Positron-Emission Tomography
- Radiopharmaceuticals/analysis
- Retrospective Studies
- Single Photon Emission Computed Tomography Computed Tomography
- Technetium Tc 99m Medronate/analysis
- Whole Body Imaging
Collapse
Affiliation(s)
- M Caglar
- Hacettepe University Medical Faculty, Department of Nuclear Medicine, Sihhiye, Ankara 06100, Turkey.
| | - O Kupik
- Hacettepe University Medical Faculty, Department of Nuclear Medicine, Sihhiye, Ankara 06100, Turkey
| | - E Karabulut
- Hacettepe University Medical Faculty, Department of Biostatistics, Sihhiye, Ankara 06100, Turkey
| | - P F Høilund-Carlsen
- Department of Nuclear Medicine, Odense University Hospital, 5000 Odense C, Denmark
| |
Collapse
|
24
|
Yao JJ, Zhan WW, Chen M, Zhang XX, Zhu Y, Fei XC, Chen XS. Sonographic Features of Ductal Carcinoma In Situ of the Breast With Microinvasion: Correlation With Clinicopathologic Findings and Biomarkers. J Ultrasound Med 2015; 34:1761-1768. [PMID: 26324758 DOI: 10.7863/ultra.15.14.07059] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/14/2014] [Accepted: 12/29/2014] [Indexed: 06/04/2023]
Abstract
OBJECTIVES To compare the sonographic results, clinicopathologic characteristics, and biomarkers in pure ductal carcinoma in situ (DCIS) of the breast and DCIS with microinvasion. METHODS A total of 218 patients with pathologically proven DCIS based on sonography in our hospital (2009-2013) were retrospectively enrolled. Clinicopathologic characteristics and biomarkers were examined. Grayscale sonographic results were investigated according to the American College of Radiology Breast Imaging Reporting and Data System lexicon, and color Doppler sonography was used to assess the vascularization distribution and degree. All variables were compared by univariate and multivariate logistic regression analyses. RESULTS All patients were female, with a mean age of 55.3 years (range, 32-78 years). One hundred sixty patients with 160 lesions had pure DCIS, and 58 patients with 58 lesions had DCIS with microinvasion. Ductal carcinoma in situ with microinvasion was more likely to have sentinel lymph node metastases, larger tumors, a higher tumor grade, human epidermal growth factor receptor 2 positivity, and a high Ki-67 index (all P < .05). Univariate analysis showed that DCIS with microinvasion was more likely to be hypoechoic with microcalcifications, have a mixed vascularization distribution (equal peripheral and internal blood flow signals), and have a high degree of vascularization (at least 2 penetrating vessels; all P < .05). Multivariate analysis indicated that the presence of microcalcifications and a high degree of vascularization were significantly and independently associated with microinvasion (both P < .001). CONCLUSIONS Our findings suggest that DCIS with microinvasion is more likely to have microcalcifications and a high degree of vascularization than pure DCIS. Patients with these sonographic features are more likely to have a high tumor grade, sentinel lymph node metastases, larger tumors, a high Ki-67 index, and human epidermal growth factor receptor 2 positivity.
Collapse
Affiliation(s)
- Jie-Jie Yao
- Departments of Ultrasound (J.-J.Y., W.-W.Z., M.C., X.-X.Z., Y.Z.,) and Pathology (X.-C.F.) and Comprehensive Breast Health Center (X.-S.C.), Rui-Jin Hospital, School of Medicine, Shanghai Jiao-Tong University, Shanghai, China
| | - Wei-Wei Zhan
- Departments of Ultrasound (J.-J.Y., W.-W.Z., M.C., X.-X.Z., Y.Z.,) and Pathology (X.-C.F.) and Comprehensive Breast Health Center (X.-S.C.), Rui-Jin Hospital, School of Medicine, Shanghai Jiao-Tong University, Shanghai, China.
| | - Man Chen
- Departments of Ultrasound (J.-J.Y., W.-W.Z., M.C., X.-X.Z., Y.Z.,) and Pathology (X.-C.F.) and Comprehensive Breast Health Center (X.-S.C.), Rui-Jin Hospital, School of Medicine, Shanghai Jiao-Tong University, Shanghai, China
| | - Xiao-Xiao Zhang
- Departments of Ultrasound (J.-J.Y., W.-W.Z., M.C., X.-X.Z., Y.Z.,) and Pathology (X.-C.F.) and Comprehensive Breast Health Center (X.-S.C.), Rui-Jin Hospital, School of Medicine, Shanghai Jiao-Tong University, Shanghai, China
| | - Ying Zhu
- Departments of Ultrasound (J.-J.Y., W.-W.Z., M.C., X.-X.Z., Y.Z.,) and Pathology (X.-C.F.) and Comprehensive Breast Health Center (X.-S.C.), Rui-Jin Hospital, School of Medicine, Shanghai Jiao-Tong University, Shanghai, China
| | - Xiao-Chun Fei
- Departments of Ultrasound (J.-J.Y., W.-W.Z., M.C., X.-X.Z., Y.Z.,) and Pathology (X.-C.F.) and Comprehensive Breast Health Center (X.-S.C.), Rui-Jin Hospital, School of Medicine, Shanghai Jiao-Tong University, Shanghai, China
| | - Xiao-Song Chen
- Departments of Ultrasound (J.-J.Y., W.-W.Z., M.C., X.-X.Z., Y.Z.,) and Pathology (X.-C.F.) and Comprehensive Breast Health Center (X.-S.C.), Rui-Jin Hospital, School of Medicine, Shanghai Jiao-Tong University, Shanghai, China
| |
Collapse
|
25
|
Buas MF, Rho JH, Chai X, Zhang Y, Lampe PD, Li CI. Candidate early detection protein biomarkers for ER+/PR+ invasive ductal breast carcinoma identified using pre-clinical plasma from the WHI observational study. Breast Cancer Res Treat 2015; 153:445-54. [PMID: 26319120 DOI: 10.1007/s10549-015-3554-5] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2015] [Accepted: 08/21/2015] [Indexed: 01/08/2023]
Abstract
Estrogen receptor (ER)-positive/progesterone receptor (PR)-positive invasive ductal carcinoma accounts for ~45 % of invasive breast cancer (BC) diagnoses in the U.S. Despite reductions in BC mortality attributable to mammography screening and adjuvant hormonal therapy, an important challenge remains the development of clinically useful blood-based biomarkers for risk assessment and early detection. The objective of this study was to identify novel protein markers for ER+/PR+ ductal BC. A nested case-control study was conducted within the Women's Health Initiative observational study. Pre-clinical plasma specimens, collected up to 12.5 months before diagnosis from 121 cases and 121 matched controls, were equally divided into training and testing sets and interrogated using a customized antibody array targeting >2000 proteins. Statistically significant differences (P < 0.05) in matched case versus control signals were observed for 39 candidates in both training and testing sets, and four markers (CSF2, RYBP, TFRC, ITGB4) remained significant after Bonferroni correction (P < 2.03 × 10(-5)). A multivariate modeling procedure based on elastic net regression with Monte Carlo cross-validation achieved an estimated AUC of 0.75 (SD 0.06). Most candidates did not overlap with those described previously for triple-negative BC, suggesting sub-type specificity. Gene set enrichment analyses identified two GO gene sets as upregulated in cases-microtubule cytoskeleton and response to hormone stimulus (P < 0.05, q < 0.25). This study has identified a pool of novel candidate plasma protein biomarkers for ER+/PR+ ductal BC using pre-diagnostic biospecimens. Further validation studies are needed to confirm these candidates and assess their potential clinical utility for BC risk assessment/early detection.
Collapse
MESH Headings
- Aged
- Aged, 80 and over
- Biomarkers, Tumor/blood
- Biomarkers, Tumor/metabolism
- Breast Neoplasms/blood
- Breast Neoplasms/diagnosis
- Breast Neoplasms/metabolism
- Carcinoma, Ductal, Breast/blood
- Carcinoma, Ductal, Breast/diagnosis
- Carcinoma, Ductal, Breast/metabolism
- Case-Control Studies
- Computational Biology/methods
- Early Detection of Cancer
- Female
- Humans
- Middle Aged
- Neoplasm Invasiveness
- Neoplasm Staging
- Proteome
- Proteomics/methods
- ROC Curve
- Receptors, Estrogen/metabolism
- Receptors, Progesterone/metabolism
- Risk Factors
Collapse
Affiliation(s)
- Matthew F Buas
- Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, 98109, USA,
| | | | | | | | | | | |
Collapse
|
26
|
Ascolani G, Occhipinti A, Liò P. Modelling circulating tumour cells for personalised survival prediction in metastatic breast cancer. PLoS Comput Biol 2015; 11:e1004199. [PMID: 25978366 PMCID: PMC4433130 DOI: 10.1371/journal.pcbi.1004199] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2014] [Accepted: 02/16/2015] [Indexed: 12/16/2022] Open
Abstract
Ductal carcinoma is one of the most common cancers among women, and the main cause of death is the formation of metastases. The development of metastases is caused by cancer cells that migrate from the primary tumour site (the mammary duct) through the blood vessels and extravasating they initiate metastasis. Here, we propose a multi-compartment model which mimics the dynamics of tumoural cells in the mammary duct, in the circulatory system and in the bone. Through a branching process model, we describe the relation between the survival times and the four markers mainly involved in metastatic breast cancer (EPCAM, CD47, CD44 and MET). In particular, the model takes into account the gene expression profile of circulating tumour cells to predict personalised survival probability. We also include the administration of drugs as bisphosphonates, which reduce the formation of circulating tumour cells and their survival in the blood vessels, in order to analyse the dynamic changes induced by the therapy. We analyse the effects of circulating tumour cells on the progression of the disease providing a quantitative measure of the cell driver mutations needed for invading the bone tissue. Our model allows to design intervention scenarios that alter the patient-specific survival probability by modifying the populations of circulating tumour cells and it could be extended to other cancer metastasis dynamics.
Collapse
Affiliation(s)
- Gianluca Ascolani
- University of Cambridge, Computer Laboratory, Cambridge, United Kingdom
| | | | - Pietro Liò
- University of Cambridge, Computer Laboratory, Cambridge, United Kingdom
| |
Collapse
|
27
|
Skondra M, Gkioka E, Kostakis ID, Pissimissis N, Lembessis P, Pectasides D, Koutsilieris M. Detection of circulating tumor cells in breast cancer patients using multiplex reverse transcription-polymerase chain reaction and specific primers for MGB, PTHRP and KRT19 correlation with clinicopathological features. Anticancer Res 2014; 34:6691-6699. [PMID: 25368276] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
AIM The aim of this study was to correlate the clinicopathological features of breast cancer patients with the positive detection of parathyroid hormone-related protein (PTHRP), cytokeratin protein 19 (KRT19) and mammaglobin (MGB) using a multiplex reverse transcription polymerase chain reaction (RT-PCR) assay developed to detect circulating tumor cells (CTCs) in peripheral blood of patients with breast cancer. PATIENTS AND METHODS Peripheral blood samples were collected from 54 breast cancer patients and 20 healthy blood donors. Subsequently, the samples were processed for RNA extraction and analyzed for the expression of PTHRP, KRT19 and MGB using specific primers and multiplex RT-PCR. RESULTS The positive detection rates in breast cancer patients for PTHRP, KRT19 and MGB were 68.5%, 63% and 22.2% and for healthy donors 10%, 0% and 10%, respectively. The statistical analysis revealed that PTHRP- and KRT19-positive detections correlated with the diagnosis of breast cancer while the combined positive detections of PTHRP-plus-KRT19 correlated with the presence of distant metastasis, especially with bone metastasis. Moreover, positive detections of KRT19 correlated with high proliferation rate of breast cancer tumors. MGB-positive detections did not add any diagnostic advantage in such analysis. CONCLUSION Multiplex-PCR based detection of CTCs using PTHRP and KRT19 primers can provide useful information for the disease.
Collapse
MESH Headings
- Adult
- Aged
- Biomarkers, Tumor
- Bone Neoplasms/blood
- Bone Neoplasms/genetics
- Bone Neoplasms/secondary
- Breast Neoplasms/blood
- Breast Neoplasms/genetics
- Breast Neoplasms/pathology
- Carcinoma, Ductal, Breast/blood
- Carcinoma, Ductal, Breast/genetics
- Carcinoma, Ductal, Breast/secondary
- Carcinoma, Lobular/blood
- Carcinoma, Lobular/genetics
- Carcinoma, Lobular/secondary
- Case-Control Studies
- Female
- Follow-Up Studies
- Humans
- Keratin-19/genetics
- Lymphatic Metastasis
- Mammaglobin A/genetics
- Middle Aged
- Neoplasm Grading
- Neoplasm Staging
- Neoplastic Cells, Circulating/pathology
- Prognosis
- RNA, Messenger/blood
- RNA, Messenger/genetics
- RNA, Neoplasm/blood
- RNA, Neoplasm/genetics
- Receptor, Parathyroid Hormone, Type 1/genetics
- Reverse Transcriptase Polymerase Chain Reaction
Collapse
Affiliation(s)
- Maria Skondra
- Department of Experimental Physiology, National and Kapodistrian University of Athens, Medical School, Athens, Greece Second Department of Internal Medicine University of Athens, Hippokratio Hospital, Athens, Greece
| | - Eliona Gkioka
- Department of Experimental Physiology, National and Kapodistrian University of Athens, Medical School, Athens, Greece
| | - Ioannis D Kostakis
- Second Department of Propedeutic Surgery National and Kapodistrian University of Athens, Medical School, Athens, Greece
| | - Nikolaos Pissimissis
- Department of Experimental Physiology, National and Kapodistrian University of Athens, Medical School, Athens, Greece
| | - Panagiotis Lembessis
- Department of Experimental Physiology, National and Kapodistrian University of Athens, Medical School, Athens, Greece
| | - Dimitrios Pectasides
- Second Department of Internal Medicine University of Athens, Hippokratio Hospital, Athens, Greece
| | - Michael Koutsilieris
- Department of Experimental Physiology, National and Kapodistrian University of Athens, Medical School, Athens, Greece
| |
Collapse
|
28
|
Debald M, Jin JP, Linke A, Walgenbach KJ, Rauch P, Zellmer A, Fimmers R, Kuhn W, Hartmann G, Walgenbach-Brünagel G. Calponin-h2: a potential serum marker for the early detection of human breast cancer? Tumour Biol 2014; 35:11121-7. [PMID: 25099617 DOI: 10.1007/s13277-014-2419-6] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2014] [Accepted: 07/29/2014] [Indexed: 01/05/2023] Open
Abstract
Early diagnosis is the key for the successful treatment of breast cancer. A serum marker for the early detection of breast cancer could significantly reduce breast cancer morbidity and mortality by bringing the time of diagnosis at an earlier and therefore still curable stage. So far, no biomarker for the early detection is available for the clinical routine. The aim of the present study was to evaluate the use of calponin-h2 as a blood-based biomarker for the early diagnosis of this disease. Using two monoclonal antibodies against calponin-h2, we developed a sandwich ELISA to analyze the serum levels of calponin-h2. In order to evaluate the diagnostic potential of this biomarker, patients with breast cancer (n = 76), benign diseases of the breast (n = 51) and healthy females (n = 24) were analyzed. Serum levels above 10 ng/ml were only observed in patients with breast cancer (n = 8; 10.5%). Further large-scale studies and preanalytic evaluations are necessary to clarify the definite role of calponin-h2 as a biomarker in breast cancer management.
Collapse
MESH Headings
- Adult
- Aged
- Aged, 80 and over
- Biomarkers/analysis
- Biomarkers, Tumor/blood
- Breast/metabolism
- Breast Neoplasms/blood
- Breast Neoplasms/diagnosis
- Calcium-Binding Proteins/blood
- Carcinoma, Ductal, Breast/blood
- Carcinoma, Ductal, Breast/diagnosis
- Carcinoma, Intraductal, Noninfiltrating/blood
- Carcinoma, Intraductal, Noninfiltrating/diagnosis
- Carcinoma, Lobular/blood
- Carcinoma, Lobular/diagnosis
- Case-Control Studies
- Enzyme-Linked Immunosorbent Assay
- Female
- Fibroadenoma/blood
- Fibroadenoma/diagnosis
- Follow-Up Studies
- Humans
- Lymphatic Metastasis
- Microfilament Proteins/blood
- Middle Aged
- Neoplasm Grading
- Neoplasm Invasiveness
- Neoplasm Staging
- Papilloma/blood
- Papilloma/diagnosis
- Prognosis
- Young Adult
- Calponins
Collapse
Affiliation(s)
- Manuel Debald
- Department of Obstetrics and Gynecology, Centre for Integrated Oncology, University of Bonn, Bonn, Germany
| | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Shike M, Doane AS, Russo L, Cabal R, Reis-Filho JS, Gerald W, Cody H, Khanin R, Bromberg J, Norton L. The effects of soy supplementation on gene expression in breast cancer: a randomized placebo-controlled study. J Natl Cancer Inst 2014; 106:dju189. [PMID: 25190728 PMCID: PMC4817128 DOI: 10.1093/jnci/dju189] [Citation(s) in RCA: 79] [Impact Index Per Article: 7.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2014] [Revised: 05/22/2014] [Accepted: 05/28/2014] [Indexed: 12/22/2022] Open
Abstract
BACKGROUND There are conflicting reports on the impact of soy on breast carcinogenesis. This study examines the effects of soy supplementation on breast cancer-related genes and pathways. METHODS Women (n = 140) with early-stage breast cancer were randomly assigned to soy protein supplementation (n = 70) or placebo (n = 70) for 7 to 30 days, from diagnosis until surgery. Adherence was determined by plasma isoflavones: genistein and daidzein. Gene expression changes were evaluated by NanoString in pre- and posttreatment tumor tissue. Genome-wide expression analysis was performed on posttreatment tissue. Proliferation (Ki67) and apoptosis (Cas3) were assessed by immunohistochemistry. RESULTS Plasma isoflavones rose in the soy group (two-sided Wilcoxon rank-sum test, P < .001) and did not change in the placebo group. In paired analysis of pre- and posttreatment samples, 21 genes (out of 202) showed altered expression (two-sided Student's t-test, P < .05). Several genes including FANCC and UGT2A1 revealed different magnitude and direction of expression changes between the two groups (two-sided Student's t-test, P < .05). A high-genistein signature consisting of 126 differentially expressed genes was identified from microarray analysis of tumors. This signature was characterized by overexpression (>2-fold) of cell cycle transcripts, including those that promote cell proliferation, such as FGFR2, E2F5, BUB1, CCNB2, MYBL2, CDK1, and CDC20 (P < .01). Soy intake did not result in statistically significant changes in Ki67 or Cas3. CONCLUSIONS Gene expression associated with soy intake and high plasma genistein defines a signature characterized by overexpression of FGFR2 and genes that drive cell cycle and proliferation pathways. These findings raise the concerns that in a subset of women soy could adversely affect gene expression in breast cancer.
Collapse
MESH Headings
- Adult
- Aged
- Apoptosis/drug effects
- Biomarkers/blood
- Breast Neoplasms/blood
- Breast Neoplasms/drug therapy
- Breast Neoplasms/metabolism
- Breast Neoplasms/pathology
- Carcinoma, Ductal, Breast/blood
- Carcinoma, Ductal, Breast/drug therapy
- Carcinoma, Ductal, Breast/metabolism
- Carcinoma, Ductal, Breast/pathology
- Caspase 3/metabolism
- Cell Proliferation/drug effects
- Dietary Supplements/adverse effects
- Female
- Gene Expression Regulation, Neoplastic/drug effects
- Genistein/blood
- Humans
- Immunohistochemistry
- Isoflavones/blood
- Ki-67 Antigen/metabolism
- Middle Aged
- Receptor, Fibroblast Growth Factor, Type 2/metabolism
- Soybean Proteins/administration & dosage
- Soybean Proteins/adverse effects
- Tissue Array Analysis
- Up-Regulation
Collapse
Affiliation(s)
- Moshe Shike
- Department of Medicine (MS, AD, LR, JB, LN) and Department of Pathology (RC, JRF, WG) and Department of Surgery (HC) and Department of Computational Biology (RK), Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College (MS, JRF, WG, HC, JB, LN).
| | - Ashley S Doane
- Department of Medicine (MS, AD, LR, JB, LN) and Department of Pathology (RC, JRF, WG) and Department of Surgery (HC) and Department of Computational Biology (RK), Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College (MS, JRF, WG, HC, JB, LN)
| | - Lianne Russo
- Department of Medicine (MS, AD, LR, JB, LN) and Department of Pathology (RC, JRF, WG) and Department of Surgery (HC) and Department of Computational Biology (RK), Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College (MS, JRF, WG, HC, JB, LN)
| | - Rafael Cabal
- Department of Medicine (MS, AD, LR, JB, LN) and Department of Pathology (RC, JRF, WG) and Department of Surgery (HC) and Department of Computational Biology (RK), Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College (MS, JRF, WG, HC, JB, LN)
| | - Jorge S Reis-Filho
- Department of Medicine (MS, AD, LR, JB, LN) and Department of Pathology (RC, JRF, WG) and Department of Surgery (HC) and Department of Computational Biology (RK), Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College (MS, JRF, WG, HC, JB, LN)
| | - William Gerald
- Department of Medicine (MS, AD, LR, JB, LN) and Department of Pathology (RC, JRF, WG) and Department of Surgery (HC) and Department of Computational Biology (RK), Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College (MS, JRF, WG, HC, JB, LN)
| | - Hiram Cody
- Department of Medicine (MS, AD, LR, JB, LN) and Department of Pathology (RC, JRF, WG) and Department of Surgery (HC) and Department of Computational Biology (RK), Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College (MS, JRF, WG, HC, JB, LN)
| | - Raya Khanin
- Department of Medicine (MS, AD, LR, JB, LN) and Department of Pathology (RC, JRF, WG) and Department of Surgery (HC) and Department of Computational Biology (RK), Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College (MS, JRF, WG, HC, JB, LN)
| | - Jacqueline Bromberg
- Department of Medicine (MS, AD, LR, JB, LN) and Department of Pathology (RC, JRF, WG) and Department of Surgery (HC) and Department of Computational Biology (RK), Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College (MS, JRF, WG, HC, JB, LN)
| | - Larry Norton
- Department of Medicine (MS, AD, LR, JB, LN) and Department of Pathology (RC, JRF, WG) and Department of Surgery (HC) and Department of Computational Biology (RK), Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College (MS, JRF, WG, HC, JB, LN)
| |
Collapse
|
30
|
Kodahl AR, Zeuthen P, Binder H, Knoop AS, Ditzel HJ. Alterations in circulating miRNA levels following early-stage estrogen receptor-positive breast cancer resection in post-menopausal women. PLoS One 2014; 9:e101950. [PMID: 25004125 PMCID: PMC4086980 DOI: 10.1371/journal.pone.0101950] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2014] [Accepted: 06/12/2014] [Indexed: 12/14/2022] Open
Abstract
Introduction Circulating microRNAs (miRNAs) exhibit remarkable stability and may serve as biomarkers in several clinical cancer settings. The aim of this study was to investigate changes in the levels of specific circulating miRNA following breast cancer surgery and evaluate whether these alterations were also observed in an independent data set. Methods Global miRNA analysis was performed on prospectively collected serum samples from 24 post-menopausal women with estrogen receptor-positive early-stage breast cancer before surgery and 3 weeks after tumor resection using global LNA-based quantitative real-time PCR (qPCR). Results Numbers of specific miRNAs detected in the samples ranged from 142 to 161, with 107 miRNAs detectable in all samples. After correction for multiple comparisons, 3 circulating miRNAs (miR-338-3p, miR-223 and miR-148a) exhibited significantly lower, and 1 miRNA (miR-107) higher levels in post-operative vs. pre-operative samples (p<0.05). No miRNAs were consistently undetectable in the post-operative samples compared to the pre-operative samples. Subsequently, our findings were compared to a dataset from a comparable patient population analyzed using similar study design and the same qPCR profiling platform, resulting in limited agreement. Conclusions A panel of 4 circulating miRNAs exhibited significantly altered levels following radical resection of primary ER+ breast cancers in post-menopausal women. These specific miRNAs may be involved in tumorigenesis and could potentially be used to monitor whether all cancer cells have been removed at surgery and/or, subsequently, whether the patients develop recurrence.
Collapse
Affiliation(s)
- Annette R. Kodahl
- Department of Oncology, Odense University Hospital and University of Southern Denmark, Odense, Denmark
- * E-mail:
| | - Pernille Zeuthen
- Department of Surgery Z, Odense University Hospital, Odense, Denmark
| | - Harald Binder
- Institute of Medical Biostatistics, Epidemiology and Informatics (IMBEI), Johannes Gutenberg University, Mainz, Germany
| | - Ann S. Knoop
- Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
| | - Henrik J. Ditzel
- Department of Oncology, Odense University Hospital and University of Southern Denmark, Odense, Denmark
- Department of Cancer and Inflammation, Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark
| |
Collapse
|
31
|
Ferroni P, Roselli M, Portarena I, Formica V, Riondino S, LA Farina F, Costarelli L, Melino A, Massimiani G, Cavaliere F, Palmirotta R, Guadagni F. Plasma plasminogen activator inhibitor-1 (PAI-1) levels in breast cancer - relationship with clinical outcome. Anticancer Res 2014; 34:1153-1161. [PMID: 24596353] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
BACKGROUND Signaling pathways triggered by increased thrombin or plasminogen activator inhibitor-1 (PAI-1) expression drastically alter the tumor microenvironment, contributing to an adverse outcome. This study aimed to evaluate the prognostic value of coagulation/fibrinolytic activities in breast cancer (BC). MATERIALS AND METHODS Coagulation/fibrinolytic activities were investigated in 187 patients with breast cancer, with respect to possible associations with clinicopathological features and survival outcomes. RESULTS Levels of plasma PAI-1 (p<0.001), D-dimer (p=0.037) and activated protein C-dependent thrombin generation (p=0.003) were higher in women with breast cancer compared to 187 healthy women. PAI-1 directly correlated with D-dimer levels (p=0.009) and Ki67 expression (p=0.027), which were both predictors of elevated PAI-1 levels at multivariate regression analysis. Cox analysis demonstrated that an elevated plasma PAI-1 level had a negative prognostic impact in terms of relapse-free (hazard ratio=2.5, p=0.021) and overall survival (hazard ratio=2.7, p=0.002). CONCLUSION Determination of plasma PAI-1 levels might provide important prognostic information in risk stratification and survival outcomes for patients with breast cancer.
Collapse
MESH Headings
- Biomarkers, Tumor/blood
- Breast Neoplasms/blood
- Breast Neoplasms/mortality
- Breast Neoplasms/pathology
- Carcinoma, Ductal, Breast/blood
- Carcinoma, Ductal, Breast/mortality
- Carcinoma, Ductal, Breast/secondary
- Carcinoma, Lobular/blood
- Carcinoma, Lobular/mortality
- Carcinoma, Lobular/secondary
- Case-Control Studies
- Enzyme-Linked Immunosorbent Assay
- Female
- Follow-Up Studies
- Humans
- Middle Aged
- Neoplasm Grading
- Neoplasm Metastasis
- Neoplasm Recurrence, Local/blood
- Neoplasm Recurrence, Local/mortality
- Neoplasm Recurrence, Local/pathology
- Neoplasm Staging
- Plasminogen Activator Inhibitor 1/blood
- Survival Rate
- Treatment Outcome
Collapse
Affiliation(s)
- Patrizia Ferroni
- Biomarker Discovery & Advanced Technologies (BioDAT) Laboratory, Scientific Institute for Research, Hospitalization and Health Care (IRCCS) San Raffaele Pisana, Via della Pisana 235, 00163, Rome, Italy.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Wu SG, He ZY, Zhou J, Sun JY, Li FY, Lin Q, Guo L, Lin HX. Serum levels of CEA and CA15-3 in different molecular subtypes and prognostic value in Chinese breast cancer. Breast 2013; 23:88-93. [PMID: 24291374 DOI: 10.1016/j.breast.2013.11.003] [Citation(s) in RCA: 75] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2013] [Revised: 10/13/2013] [Accepted: 11/15/2013] [Indexed: 11/19/2022] Open
Abstract
The prognostic significance of preoperative carcinoembryonic antigen (CEA) and cancer antigen 15-3 (CA15-3) levels in breast cancer is controversial. This study evaluated the prognostic value of preoperative serum CEA and CA15-3 levels in Chinese breast cancer patients. A total of 470 patients with breast cancer had preoperative CEA and CA15-3 concentrations measured. The relationships between preoperative concentration and clinicopathological factors and outcomes were determined. CEA and CA15-3 levels were increased in 34 (7.2%) and 58 (12.3%) patients, respectively. Elevations of serum CEA and CA-15-3 levels correlated with the primary tumor size and axillary lymph node status. CEA levels were lower in patients with triple-negative breast cancer than in those with other subtypes (P = 0.002). The 5-year distant metastasis-free survival (DMFS), disease-free survival (DFS), and overall survival (OS) of CEA-negative vs. CEA-positive patients were 84.1% vs. 54.5% (P < 0.001), 82.7% vs. 54.8% (P < 0.001), and 89.7% vs. 78.5% (P = 0.007), respectively. The 5-year DMFS, DFS, and OS of CA15-3-negative vs. CA15-3-positive patients were 84.0% vs. 69.6% (P = 0.002), 83.0% vs. 66.2% (P < 0.001), 90.9% vs. 74.2% (P = 0.005), respectively. Multivariate analysis of prognosis indicated that CEA and CA15-3 levels were independent prognostic factors for DMFS (P = 0.021) and DFS (P = 0.032), and DFS (P = 0.014) and OS (P = 0.032), respectively. Serum levels of CEA and CA15-3 may differ in breast cancer molecular subtypes and preoperative levels of CEA and CA15-3 have a significant effect on prognosis in Chinese women with breast cancer.
Collapse
Affiliation(s)
- San-gang Wu
- Xiamen Cancer Center, Department of Radiation Oncology, The First Affiliated Hospital of Xiamen University, Xiamen, People's Republic of China
| | - Zhen-yu He
- State Key Laboratory of Oncology in Southern China, Department of Radiation Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, People's Republic of China
| | - Juan Zhou
- Xiamen Cancer Center, Department of Obstetrics and Gynecology, The First Affiliated Hospital of Xiamen University, Xiamen, People's Republic of China
| | - Jia-yuan Sun
- State Key Laboratory of Oncology in Southern China, Department of Radiation Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, People's Republic of China
| | - Feng-yan Li
- State Key Laboratory of Oncology in Southern China, Department of Radiation Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, People's Republic of China
| | - Qin Lin
- Xiamen Cancer Center, Department of Radiation Oncology, The First Affiliated Hospital of Xiamen University, Xiamen, People's Republic of China
| | - Ling Guo
- State Key Laboratory of Oncology in Southern China, Department of Nasopharyngeal Carcinoma, Sun Yat-Sen University Cancer Center, Guangzhou, People's Republic of China.
| | - Huan-xin Lin
- State Key Laboratory of Oncology in Southern China, Department of Radiation Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, People's Republic of China.
| |
Collapse
|
33
|
Berliere M, Duhoux FP, Dalenc F, Baurain JF, Dellevigne L, Galant C, Van Maanen A, Piette P, Machiels JP. Tamoxifen and ovarian function. PLoS One 2013; 8:e66616. [PMID: 23840510 PMCID: PMC3695994 DOI: 10.1371/journal.pone.0066616] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2012] [Accepted: 05/07/2013] [Indexed: 11/18/2022] Open
Abstract
BACKGROUND Some studies suggest that the clinical parameter "amenorrhea" is insufficient to define the menopausal status of women treated with chemotherapy or tamoxifen. In this study, we investigated and compared the ovarian function defined either by clinical or biological parameters in pre-menopausal breast cancer patients treated with tamoxifen administered as adjuvant therapy. MATERIALS AND METHODS Between 1999 and 2003, 138 premenopausal patients consecutively treated for early breast cancer were included. Sixty-eight received tamoxifen in monotherapy as the only adjuvant systemic treatment (Group I) and 70 were treated with tamoxifen after adjuvant chemotherapy (Group II). All patients had a confirmed premenopausal status based on clinical parameters and hormonal values at study entry. They were followed prospectively every 3 months for 3 years: menses data, physical examination and blood tests (LH, FSH, 17-beta-estradiol). Vaginal ultrasonography was carried out every 6 months. After 3 years, prospective evaluation was completed and monitoring of ovarian function was performed as usual in our institution (1x/year). All data were retrospectively evaluated in 2011. RESULTS Three patients were excluded from the study in group I and 2 were excluded in group II. Patients were divided into 4 subgroups according to clinical data, i.e. menses patterns. These patterns were assessed by questionnaires. a: Regular menses (>10 cycles/year) b: Oligomenorrhea (5 to 9 cycles/year) c: Severe oligomenorrhea (1 to 4 cycles/year) d: Complete amenorrhea Estrogen levels did not appear to have any impact on disease-free survival rates after 3 or 8 years. FSH values were also documented and analyzed. They exhibited the same profile as estradiol values. CONCLUSIONS Amenorrhea is an insufficient parameter to define menopausal status in patients receiving tamoxifen. Low estradiol levels must be coupled with other biological parameters to characterize endocrine status. These data are very important for the choice of endocrine therapy.
Collapse
Affiliation(s)
- Martine Berliere
- Clinique du sein, Centre du Cancer, Cliniques universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgium.
| | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Gruber I, Landenberger N, Staebler A, Hahn M, Wallwiener D, Fehm T. Relationship between circulating tumor cells and peripheral T-cells in patients with primary breast cancer. Anticancer Res 2013; 33:2233-2238. [PMID: 23645781] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Abstract
BACKGROUND Detection of circulating tumor cells (CTCs) in the peripheral blood of patients with primary breast cancer is associated with poor clinical outcome. Recent studies have found evidence for immunological influence on tumor cell dormancy. We therefore investigated the relationship between peripheral T-cells and CTCs, as immunological factors may contribute to the fate of CTCs. MATERIALS AND METHODS The peripheral blood immune status of 116 patients with primary breast cancer was analyzed by flow cytometry. Results were correlated with the presence of CTCs and clinicopathological parameters of these patients. RESULTS Appearance of CTCs was significantly associated with grade III tumors (p<0.05). Interestingly, CTC-positive patients presented with a significant increase of peripheral CD95(FAS)-positive T-helper cells. As immune response is regulated by CD95(APO-1/FAS)-CD95ligand interaction and tumor cells induce apoptosis via the CD95/CD95L (ligand) pathway, this might lead to tumor cell escape by apoptotic T-helper cells. CONCLUSION Absence of T-cell help at the time of priming may result in a loss of long-term antigen-activation of CD8 lymphocytes and could lead to an ineffective anti-tumor cell response. This might contribute to systemic immunosuppression and open the door for tumor cell dormancy.
Collapse
MESH Headings
- Apoptosis
- Breast Neoplasms/blood
- Breast Neoplasms/immunology
- Breast Neoplasms/pathology
- Carcinoma, Ductal, Breast/blood
- Carcinoma, Ductal, Breast/immunology
- Carcinoma, Ductal, Breast/pathology
- Carcinoma, Intraductal, Noninfiltrating/blood
- Carcinoma, Intraductal, Noninfiltrating/immunology
- Carcinoma, Intraductal, Noninfiltrating/pathology
- Female
- Flow Cytometry
- Follow-Up Studies
- Humans
- Neoplasm Grading
- Neoplasm Staging
- Neoplastic Cells, Circulating/immunology
- Neoplastic Cells, Circulating/metabolism
- Prognosis
- T-Lymphocyte Subsets/immunology
- Tumor Escape
- fas Receptor/metabolism
Collapse
Affiliation(s)
- Ines Gruber
- Department of Obstetrics and Gynecology,University of Tuebingen, Calwer Straße. 7, 72076 Tuebingen, Germany.
| | | | | | | | | | | |
Collapse
|
35
|
Panis C, Herrera AC, Victorino VJ, Aranome AMF, Cecchini R. Screening of circulating TGF-β levels and its clinicopathological significance in human breast cancer. Anticancer Res 2013; 33:737-742. [PMID: 23393376] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
BACKGROUND Transforming growth factor beta-1 (TGF-β1) participation in breast cancer development and metastasis is well-established, however, the clinical meaning of its circulating levels in women with breast cancer is poorly understood. AIM To characterize the levels of TGF-β1 in plasma from women with breast cancer and to associate them with the main clinical factors associated with disease prognosis. PATIENTS AND METHODS TGF-β1 levels were measured by Enzyme-linked immunoassay (ELISA). Clinicopathological data were also assessed. RESULTS Women bearing triple-negative tumors presented significantly reduced levels of this cytokine when compared to the other subtypes (p=0.0338). Patients with metastases exhibited lower levels of TGF-β1 than the non-metastatic cohort (p=0.0442). Patients with early-onset disease had the highest plasma TGF-β1 levels (p=0.0036). Doxorubicin chemotherapy induced a reduction in TGF-β1 level, promptly after drug infusion (p=0.0494). Patients with TGF-β1 levels lower than 20 pg/ml exhibited a tendency to have a reduced overall survival in a 40-month follow-up. CONCLUSION Lower levels of circulating TGF-β1 are associated with a poor disease prognosis.
Collapse
Affiliation(s)
- Carolina Panis
- Laboratory of Pathophysiology and Free Radicals, Department of General Pathology-Center of Biological Sciences, State University of Londrina, 86051-990 Londrina, Brazil.
| | | | | | | | | |
Collapse
|
36
|
Chen W, Cai F, Zhang B, Barekati Z, Zhong XY. The level of circulating miRNA-10b and miRNA-373 in detecting lymph node metastasis of breast cancer: potential biomarkers. Tumour Biol 2012; 34:455-62. [PMID: 23238818 DOI: 10.1007/s13277-012-0570-5] [Citation(s) in RCA: 125] [Impact Index Per Article: 10.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2012] [Accepted: 10/19/2012] [Indexed: 12/13/2022] Open
Abstract
MicroRNAs (miRNAs) are a class of small noncoding RNAs whose expression changes are associated with cancer development and invasion. We hypothesized that miR-10b and miR-373, which are increased in lymphatic metastatic tissues, could be directly assayed in the plasma and used to detect the lymph node status of breast cancer patients. Between November 2009 and January 2012, 35 breast ductal carcinoma patients with lymph node metastasis (N patients), 25 ductal carcinoma patients without lymph node metastasis (N(0) patients), and ten healthy female donors were enrolled in the study. Circulating miR-10b and miR-373 were determined in preoperative plasma samples by reverse transcription quantitative real-time PCR assay. In preliminary tests, the plasma levels of circulating miR-10b and miR-373 were found to be significantly higher in ten breast cancer patients with lymph node metastasis compared to ten N(0) patients and ten normal donors (P < 0.01). On validation analysis, the median value level of miR-10b in the 35 N patients was 4.44-fold (P < 0.01) increased, and miR-373 was 4.38-fold (P < 0.01) increased in comparison to the 25 N(0) patients. MiR-10b was used for differentiation of N patients from N(0) patients; the odds ratio was 2.19, and the value of the area under the receiver-operating curve (AUC) was 0.80, with sensitivity of 71 % and specificity of 72 %. For miR-373, the odds ratio was 2.62, and the AUC was 0.84, with sensitivity of 68 % and specificity of 89 %. A combination of the two circulating miRNAs further enhanced the sensitivity to 72 % and the specificity to 94.3 %. Our data suggest that circulating miRNA-10b and miRNA-373 are potential biomarkers for detecting the lymph node status of breast cancer.
Collapse
Affiliation(s)
- Weijie Chen
- Laboratory for Gynecological Oncology, University Women's Hospital, Department of Biomedicine, University of Basel, Hebelstrasse 20, CH4031, Basel, Switzerland
| | | | | | | | | |
Collapse
|
37
|
Zebisch M, Kölbl AC, Schindlbeck C, Neugebauer J, Heublein S, Ilmer M, Rack B, Friese K, Jeschke U, Andergassen U. Quantification of breast cancer cells in peripheral blood samples by real-time rt-PCR. Anticancer Res 2012; 32:5387-5391. [PMID: 23225441] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
BACKGROUND Circulating tumour cells (CTCs) are cells that have detached from a primary tumour, circulate in the peripheral blood, and are considered to be the main root of distant metastases. We present a method for the detection of CTCs by real-time PCR on different cytokeratin markers. MATERIALS AND METHODS Blood samples of a healthy donor were mixed with specific numbers of cells from different breast carcinoma cell line cells. RNA was isolated from the samples and transcribed into cDNA. TaqMan real-time PCR for cytokeratins 8, 18 and 19 was carried out and was correlated to that of 18S. RESULTS Cytokeratin gene expression increased in all samples, when as few as 10 tumour cells were added. In the CAMA-1 cell line, the increase was even greater the more cells were added. CONCLUSION By this methodology, cells from mammary carcinoma cell lines can be detected in blood samples. Its benefit will be validated in samples from patients with breast cancer.
Collapse
Affiliation(s)
- Michael Zebisch
- Department of Obstetrics and Gynaecology, Ludwig-Maximilians-University of Munich, Maistrasse 11, D-80337 Munich, Germany
| | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Herrera ACSA, Panis C, Victorino VJ, Campos FC, Colado-Simão AN, Cecchini AL, Cecchini R. Molecular subtype is determinant on inflammatory status and immunological profile from invasive breast cancer patients. Cancer Immunol Immunother 2012; 61:2193-201. [PMID: 22618884 PMCID: PMC11028631 DOI: 10.1007/s00262-012-1283-8] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2012] [Accepted: 05/03/2012] [Indexed: 10/28/2022]
Abstract
Breast cancer consists in a chronic inflammatory disease with multiple biological and clinical behaviors. Based on high throughput technologies data, this disease is currently classified according to the molecular expression of estrogen (ER), progesterone (PR) and human epidermal growth factor (HER-2) receptors. In this study, we defined the inflammatory profile of the main molecular subtypes of breast cancer patients: luminal (ER and PR positive, HER-2 negative), HER-2 enriched (HER-2 positive) and triple negative (ER, PR and HER-2 negative). Cytokines panel was assessed by measurement of TNF-α, TGF-β, IL-1, IL-10 and IL-12 plasmatic levels. Oxidative profile was assessed by determination of lipid peroxidation, total antioxidant capacity of plasma, malondialdehyde levels, carbonyl content and nitric oxide (NO). Clinical data were correlated with inflammatory findings. Our findings demonstrated that patients bearing the luminal subtype displayed high TNF-α, TGF-β and enhanced oxidative stress levels associated with reduced IL-12. HER-2-enriched group exhibited higher levels of TNF-α, IL-12 and TGF-β associated with enhanced oxidative stress. Triple-negative subtype exhibited the most aggressive profile of disease behavior, with reduction in both TNF-α and TGF-β, with high levels of lipid peroxidation and NO. The clinical importance of our findings lies in the fact that the inflammatory status varies in distinct ways due to molecular subtype of breast cancer, opening potential therapeutic targets to future therapies.
Collapse
Affiliation(s)
- A. C. S. A. Herrera
- Laboratory of Pathophysiology and Free Radicals, Department of General Pathology, Center of Biological Sciences, State University of Londrina, Londrina, 86051-990 Brazil
| | - C. Panis
- Laboratory of Pathophysiology and Free Radicals, Department of General Pathology, Center of Biological Sciences, State University of Londrina, Londrina, 86051-990 Brazil
| | - V. J. Victorino
- Laboratory of Pathophysiology and Free Radicals, Department of General Pathology, Center of Biological Sciences, State University of Londrina, Londrina, 86051-990 Brazil
| | - F. C. Campos
- Laboratory of Pathophysiology and Free Radicals, Department of General Pathology, Center of Biological Sciences, State University of Londrina, Londrina, 86051-990 Brazil
| | - A. N. Colado-Simão
- Laboratory of Pathophysiology and Free Radicals, Department of General Pathology, Center of Biological Sciences, State University of Londrina, Londrina, 86051-990 Brazil
| | - A. L. Cecchini
- Laboratory of Pathophysiology and Free Radicals, Department of General Pathology, Center of Biological Sciences, State University of Londrina, Londrina, 86051-990 Brazil
| | - R. Cecchini
- Laboratory of Pathophysiology and Free Radicals, Department of General Pathology, Center of Biological Sciences, State University of Londrina, Londrina, 86051-990 Brazil
| |
Collapse
|
39
|
Stebbing J, Sharma A, North B, Athersuch TJ, Zebrowski A, Pchejetski D, Coombes RC, Nicholson JK, Keun HC. A metabolic phenotyping approach to understanding relationships between metabolic syndrome and breast tumour responses to chemotherapy. Ann Oncol 2012; 23:860-6. [PMID: 21821546 DOI: 10.1093/annonc/mdr347] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023] Open
Abstract
PURPOSE Breast cancer is associated with adverse outcomes in patients with the metabolic syndrome phenotype. To study this further, we examined the relationship between serum metabolite levels and the components of metabolic syndrome with treatment outcomes in breast cancer. METHODS A total of 88 women with measurable breast cancer were studied; their serum metabolites as assessed by (1)H nuclear magnetic resonance spectroscopy, blood pressure, lipids, glucose, body mass index and waist circumference were recorded and correlated with treatment response. RESULTS We identified metabolic syndrome in approximately half of our cohort (42 patients) and observed a significant trend (P = 0.03) of increased incidence of metabolic syndrome in partial response (33.3%), stable disease (42.9%) and progressive disease groups (66.1%). High blood sugar predicted a poor response (P < 0.001). Logistic regression of metabonomic data demonstrated that high lactate (P = 0.03) and low alanine (P = 0.01) combined with high glucose (P = 0.01) were associated with disease progression. CONCLUSIONS Metabolic syndrome is commonly observed in metastatic breast cancer and these patients have poorer outcomes. These data, which support our previous findings, suggest that high blood glucose as part of metabolic syndrome is associated with a poor response in breast cancer. They also validate new therapeutic approaches that focus on metabolism.
Collapse
Affiliation(s)
- J Stebbing
- Section of Oncology, Department of Surgery and Cancer, Faculty of Medicine, Imperial College, London, UK.
| | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Herranz M, Pombo M, Menendez-Rodriguez P, Arias JI, Ruibal A. Breast carcinomas with hyperprolactinemia at the time of diagnosis-clinico-biological association. Gynecol Endocrinol 2012; 28:278-81. [PMID: 22420628 DOI: 10.3109/09513590.2011.631631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
AIM To analyse association between preoperative hyperprolactinemia serum levels and clinical and biological features of breast tumors. METHODS Serum levels of prolactin were measured in 253 women with invasive breast cancer. Clinical and biological parameters analysed were age, size, lymph node involvement, distant metastasis and immunohistochemical expression of estrogen receptor, progesterone receptor, androgen receptor, bcl-2, p53 and Ki67. RESULTS In ductal carcinomas hyperprolactinemia were associated with high age (p = 0.017), and with bcl-2 + + + expression (p = 0.017). Furthermore, serum prolactin values were significantly higher in bcl-2 +++ cases vs negative (p = 0.029); the same happened when we considered the positivity threshold of 25 ng/mL (p = 0.015). CONCLUSION Is possible to detect in 6% of infiltrating ductal breast carcinomas hyperprolactinemia (>25 ng/mL), being associated only with increasing age, but not with other clinical or biological factors; and 2) the most surprising data was the association between prolactinemia (qualitative (>25 ng/mL) and quantitative) and intense bcl-2 tissue expression, which suggests that, probably, this (prolactinemia) is not a sign of worse prognosis and evolution.
Collapse
MESH Headings
- Age Factors
- Aged
- Aged, 80 and over
- Biomarkers, Tumor/blood
- Biomarkers, Tumor/metabolism
- Breast Neoplasms/blood
- Breast Neoplasms/complications
- Breast Neoplasms/diagnosis
- Carcinoma, Ductal, Breast/blood
- Carcinoma, Ductal, Breast/complications
- Carcinoma, Ductal, Breast/diagnosis
- Female
- Humans
- Hyperprolactinemia/blood
- Hyperprolactinemia/complications
- Middle Aged
- Prognosis
- Prolactin/blood
- Proto-Oncogene Proteins c-bcl-2/metabolism
- Receptors, Androgen/metabolism
- Receptors, Estrogen/metabolism
- Receptors, Progesterone/metabolism
Collapse
Affiliation(s)
- M Herranz
- Molecular Oncology and Imaging Program, Complejo Hospitalario Universitario, Santiago de Compostela, A Coruña, Spain.
| | | | | | | | | |
Collapse
|
41
|
|
42
|
Globa AG, Alekseev II, Varlamov DA, Vishnevskiĭ AA. [The diagnostic value of RNA oncomarkers in evaluation of malignant breast tumors]. Biomed Khim 2012; 57:677-80. [PMID: 22359925 DOI: 10.18097/pbmc20115706677] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
The levels of the RNA oncomarkers, telomerase (hTERT), cytokeratin-19 (CK-19) and mammaglobin (MAM) have been investigated in capillary blood of female patients with mammary ductal carcinoma. The study revealed overexpression of all three factors in patients with this pathology. This overexpression was not found in healthy donors and female patients with mammary fibroadenoma. Levels of the RNA oncomarkers return to the normal level within 10 days after successful tumor resection. These results have been used for the development of diagnostic kits, which may be applicable for differential diagnostics, screening and postoperation monitoring of patients with malignant breast tumors
Collapse
|
43
|
Zeleniuch-Jacquotte A, Afanasyeva Y, Kaaks R, Rinaldi S, Scarmo S, Liu M, Arslan AA, Toniolo P, Shore RE, Koenig KL. Premenopausal serum androgens and breast cancer risk: a nested case-control study. Breast Cancer Res 2012; 14:R32. [PMID: 22339988 PMCID: PMC3496150 DOI: 10.1186/bcr3117] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2011] [Revised: 01/20/2012] [Accepted: 02/16/2012] [Indexed: 11/10/2022] Open
Abstract
INTRODUCTION Prospective epidemiologic studies have consistently shown that levels of circulating androgens in postmenopausal women are positively associated with breast cancer risk. However, data in premenopausal women are limited. METHODS A case-control study nested within the New York University Women's Health Study was conducted. A total of 356 cases (276 invasive and 80 in situ) and 683 individually-matched controls were included. Matching variables included age and date, phase, and day of menstrual cycle at blood donation. Testosterone, androstenedione, dehydroandrosterone sulfate (DHEAS) and sex hormone-binding globulin (SHBG) were measured using direct immunoassays. Free testosterone was calculated. RESULTS Premenopausal serum testosterone and free testosterone concentrations were positively associated with breast cancer risk. In models adjusted for known risk factors of breast cancer, the odds ratios for increasing quintiles of testosterone were 1.0 (reference), 1.5 (95% confidence interval (CI), 0.9 to 2.3), 1.2 (95% CI, 0.7 to 1.9), 1.4 (95% CI, 0.9 to 2.3) and 1.8 (95% CI, 1.1 to 2.9; Ptrend = 0.04), and for free testosterone were 1.0 (reference), 1.2 (95% CI, 0.7 to 1.8), 1.5 (95% CI, 0.9 to 2.3), 1.5 (95% CI, 0.9 to 2.3), and 1.8 (95% CI, 1.1 to 2.8, Ptrend = 0.01). A marginally significant positive association was observed with androstenedione (P = 0.07), but no association with DHEAS or SHBG. Results were consistent in analyses stratified by tumor type (invasive, in situ), estrogen receptor status, age at blood donation, and menopausal status at diagnosis. Intra-class correlation coefficients for samples collected from 0.8 to 5.3 years apart (median 2 years) in 138 cases and 268 controls were greater than 0.7 for all biomarkers except for androstenedione (0.57 in controls). CONCLUSIONS Premenopausal concentrations of testosterone and free testosterone are associated with breast cancer risk. Testosterone and free testosterone measurements are also highly reliable (that is, a single measurement is reflective of a woman's average level over time). Results from other prospective studies are consistent with our results. The impact of including testosterone or free testosterone in breast cancer risk prediction models for women between the ages of 40 and 50 years should be assessed. Improving risk prediction models for this age group could help decision making regarding both screening and chemoprevention of breast cancer.
Collapse
Affiliation(s)
- Anne Zeleniuch-Jacquotte
- Department of Environmental Medicine, New York University School of Medicine, 650 First Avenue, New York, NY 10016, USA
- New York University Cancer Institute, New York University School of Medicine, 530 First Avenue, New York, NY 10016, USA
| | - Yelena Afanasyeva
- Department of Environmental Medicine, New York University School of Medicine, 650 First Avenue, New York, NY 10016, USA
| | - Rudolf Kaaks
- Division of Cancer Epidemiology, German Cancer Research Centre, Im Neuenheimer Feld 280, D-69120 Heidelberg, Germany
| | - Sabina Rinaldi
- International Agency for Research on Cancer, 150, Cours Albert Thomas, 69372 Lyon Cedex 08, France
| | - Stephanie Scarmo
- Department of Environmental Medicine, New York University School of Medicine, 650 First Avenue, New York, NY 10016, USA
| | - Mengling Liu
- Department of Environmental Medicine, New York University School of Medicine, 650 First Avenue, New York, NY 10016, USA
- New York University Cancer Institute, New York University School of Medicine, 530 First Avenue, New York, NY 10016, USA
| | - Alan A Arslan
- Department of Environmental Medicine, New York University School of Medicine, 650 First Avenue, New York, NY 10016, USA
- New York University Cancer Institute, New York University School of Medicine, 530 First Avenue, New York, NY 10016, USA
- Department of Obstetrics and Gynecology, New York University School of Medicine, 550 First Avenue, New York, NY 10016, USA
| | - Paolo Toniolo
- Department of Environmental Medicine, New York University School of Medicine, 650 First Avenue, New York, NY 10016, USA
- New York University Cancer Institute, New York University School of Medicine, 530 First Avenue, New York, NY 10016, USA
- Department of Obstetrics and Gynecology, New York University School of Medicine, 550 First Avenue, New York, NY 10016, USA
- Unit of Cancer Epidemiology, Institute of Social and Preventive Medicine, Centre Hospitalier Universitaire Vaudois, Biopôle 1, 2 Route de la Corniche, CH-1066 Epalinges, Switzerland
| | - Roy E Shore
- Department of Environmental Medicine, New York University School of Medicine, 650 First Avenue, New York, NY 10016, USA
- Radiation Effects Research Foundation, 5-2 Hijiyama Park, Minami-ku, Hiroshima, 732-0815, Japan
| | - Karen L Koenig
- Department of Environmental Medicine, New York University School of Medicine, 650 First Avenue, New York, NY 10016, USA
- New York University Cancer Institute, New York University School of Medicine, 530 First Avenue, New York, NY 10016, USA
| |
Collapse
|
44
|
Georgescu R, Coroş MF, Stolnicu S, Podeanu D, Sorlea S, Roşca A, Copotoiu C. [Prognostic factors in breast cancer]. Rev Med Chir Soc Med Nat Iasi 2012; 116:262-267. [PMID: 23077906] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
UNLABELLED Survival in breast cancer is determined by many factors, their influence is different. The aim of the study is to assess the impact on survival of various prognostic factors. MATERIAL AND METHODS We studied a total of 198 cases of histologically confirmed breast cancer patients, and we evaluated the impact of prognostic factors on survival. RESULTS The most important factor influencing survival is the preset of axillary metastasis(p: 0.0001). Other important prognostic factors are: tumor size (p: 0.003), tumor grading (p: 0.0025), N stage (p: 0.0001.) lymphovascular invasion (p 0.0005) and Nottingham Prognostic Index (p: 0.0109). The factors with no impact on survival were: histological type (p: 0.82), number of lymph nodes affected(p: 0.23), tumor necrosis(p: 0.49) and inflammatory infiltration (p: 0.2). CONCLUSIONS The most important prognostic factors are: axillary metastasis followed by tumor grading, NPI and lymphovascular invasion.
Collapse
MESH Headings
- Adult
- Biomarkers, Tumor/blood
- Breast Neoplasms/blood
- Breast Neoplasms/mortality
- Breast Neoplasms/pathology
- Breast Neoplasms/surgery
- Carcinoma, Ductal, Breast/blood
- Carcinoma, Ductal, Breast/mortality
- Carcinoma, Ductal, Breast/pathology
- Carcinoma, Ductal, Breast/surgery
- Carcinoma, Intraductal, Noninfiltrating/blood
- Carcinoma, Intraductal, Noninfiltrating/mortality
- Carcinoma, Intraductal, Noninfiltrating/pathology
- Carcinoma, Intraductal, Noninfiltrating/surgery
- Female
- Humans
- Lymph Nodes/pathology
- Lymph Nodes/surgery
- Mastectomy
- Middle Aged
- Neoplasm Grading
- Neoplasm Invasiveness
- Neoplasm Staging
- Predictive Value of Tests
- Prognosis
- Retrospective Studies
- Romania/epidemiology
- Sensitivity and Specificity
- Sentinel Lymph Node Biopsy
- Severity of Illness Index
- Survival Rate
- Tumor Necrosis Factor-alpha/blood
Collapse
Affiliation(s)
- R Georgescu
- Universitatea de Medicină si Farmacie Târgu Mureş
| | | | | | | | | | | | | |
Collapse
|
45
|
Zagouri F, Sergentanis TN, Provatopoulou X, Kalogera E, Chrysikos D, Lymperi M, Papadimitriou CA, Zografos E, Bletsa G, Kalles VS, Zografos GC, Gounaris A. Serum levels of HSP90 in the continuum of breast ductal and lobular lesions. In Vivo 2011; 25:669-672. [PMID: 21709012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
BACKGROUND Heat-shock protein 90 (HSP90) is an abundant protein in mammalian cells. It interacts with a variety of proteins that play key roles in breast neoplasia. This is the first study to assess serum levels of HSP90 in atypical ductal hyperplasia (ADH), lobular neoplasia (LN), ductal carcinoma in situ (DCIS), invasive ductal carcinoma (IDC) and infiltrative lobular carcinoma (ILC). PATIENTS AND METHODS Serum concentrations of HSP90 in women with benign (n=34), ADH (n=26), DCIS (n=30), IDC (n=29), LN (n=20) and ILC (n=9) lesions were determined with immunoenzymatic assays. For the evaluation of serum concentrations along the transition from benign through precursor and preinvasive to invasive lesion, the severity of diagnosis was treated as an ordinal variable. RESULTS No significant association was demonstrated between serum HSP90 levels and the severity of the lesion in ductal and lobular series. The post hoc comparison between the lobular and ductal precursor lesions (i.e. ADH vs. LN) did not yield a statistically significant difference. Similarly, the post hoc comparison between the lobular and ductal invasive carcinomas (i.e. IDC vs. ILC) did not point to a statistically significant difference. CONCLUSION This is the first study evaluating HSP90 serum levels in both lobular and ductal lesions of the breast. Contrary to published pathological findings according to which HSP90 exhibits significant variability along both series, such a finding was not replicated for the level of serum HSP90 concentrations.
Collapse
MESH Headings
- Adult
- Aged
- Aged, 80 and over
- Breast Diseases/blood
- Breast Diseases/pathology
- Breast Neoplasms/blood
- Breast Neoplasms/pathology
- Carcinoma, Ductal, Breast/blood
- Carcinoma, Ductal, Breast/pathology
- Carcinoma, Intraductal, Noninfiltrating/blood
- Carcinoma, Intraductal, Noninfiltrating/pathology
- Carcinoma, Lobular/blood
- Carcinoma, Lobular/pathology
- Female
- HSP90 Heat-Shock Proteins/blood
- Humans
- Hyperplasia/blood
- Hyperplasia/pathology
- Middle Aged
Collapse
Affiliation(s)
- Flora Zagouri
- Breast Unit, First Department of Propaedeutic Surgery, Hippokratio Hospital, School of Medicine, University of Athens, Greece
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Konjevic G, Radenkovic S, Srdic T, Jurisic V, Stamatovic L, Milovic M. Association of decreased NK cell activity and IFNγ expression with pSTAT dysregulation in breast cancer patients. J BUON 2011; 16:219-226. [PMID: 21766489] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
PURPOSE Impaired IFNγ production in peripheral blood lymphocytes (PBL) and their subsets reflects immunosuppression and inadequate antitumor immune response in cancer patients. Decreased function of natural killer (NK) cells has not been investigated in breast cancer with respect to altered pSTAT signaling pathways. METHODS PBL of breast cancer patients and healthy controls were analyzed for IFNγ and pSTAT1 expression and NK cell activity using flow cytometry and (51)Cr-release assay, respectively. The level of pSTAT1, 3 and 5 was investigated by Western blotting. RESULTS Our results indicated that PBL and CD3(-) CD16(+) NK cells of patients had significantly lower level of IFNγ. The patients had a significantly decreased NK cell cytotoxicity compared to controls, with the decrease being dependent on the stage of disease. Positive correlation between IFNγ level in PBL and NK cytotoxicity in controls and patients was also shown. The PBL of patients, compared to controls, expressed lower level of pSTAT1, 3 and 5. The patients' T and NK cell subsets had lower pSTAT1 level. CONCLUSION This study indicates that pSTAT1 in PBL of breast cancer patients could be a biomarker of decreased NK cell cytotoxicity and IFNγlevel that are associated with progression of this disease.
Collapse
MESH Headings
- Adult
- Aged
- Blotting, Western
- Bone Neoplasms/blood
- Bone Neoplasms/immunology
- Bone Neoplasms/secondary
- Breast Neoplasms/blood
- Breast Neoplasms/immunology
- Breast Neoplasms/pathology
- Carcinoma, Ductal, Breast/blood
- Carcinoma, Ductal, Breast/immunology
- Carcinoma, Ductal, Breast/secondary
- Case-Control Studies
- Cytotoxicity, Immunologic
- Female
- Flow Cytometry
- Follow-Up Studies
- Humans
- Interferon-gamma/blood
- Killer Cells, Natural/immunology
- Killer Cells, Natural/metabolism
- Killer Cells, Natural/pathology
- Liver Neoplasms/blood
- Liver Neoplasms/immunology
- Liver Neoplasms/secondary
- Lung Neoplasms/blood
- Lung Neoplasms/immunology
- Lung Neoplasms/secondary
- Lymphatic Metastasis
- Lymphocytes
- Middle Aged
- Neoplasm Staging
- Phosphorylation
- STAT Transcription Factors/blood
- Signal Transduction
Collapse
Affiliation(s)
- G Konjevic
- Institute of Oncology and Radiology of Serbia, Department of Experimental Oncology, Belgrade, Serbia.
| | | | | | | | | | | |
Collapse
|
47
|
Manole A, Azoicăi D, Todi P, Manole M, Ivan A. [Assessment of some laboratory, imaging and anatomical-pathological investigations on a lot of 104 patients diagnosed with breast cancer and appear in the list of family doctor from the city of Iasi]. Rev Med Chir Soc Med Nat Iasi 2011; 115:171-175. [PMID: 21688573] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
UNLABELLED The aim of study was to assess some investigations in female patients with benign and malignant breast diseases. MATERIAL AND METHODS The study was performed on a sample of 104 patients registered with breast tumors, at family physicians' offices from Iasi, Romania. RESULTS Impaired glucose tolerance was associated with 34.2% of patient with breast tumors, and hypercholesterolemia with 25.9% of them. Anatomo-pathological assessments included aspiration puncture and biopsy, extemporaneous biopsy, and paraffin-embedded exam. Invasive carcinoma was the most frequent histo-pathological type (42.1%). CONCLUSIONS; Further investigations on tumor markers are needed in all patients with in situ neoplasia and breast carcinomas.
Collapse
MESH Headings
- Adult
- Aged
- Biomarkers, Tumor/analysis
- Biomarkers, Tumor/blood
- Biopsy
- Body Mass Index
- Breast Diseases/diagnosis
- Breast Neoplasms/blood
- Breast Neoplasms/diagnosis
- Breast Neoplasms/epidemiology
- Breast Neoplasms/pathology
- Carcinoma, Ductal, Breast/blood
- Carcinoma, Ductal, Breast/diagnosis
- Carcinoma, Ductal, Breast/epidemiology
- Carcinoma, Ductal, Breast/pathology
- Diabetes Complications/epidemiology
- Female
- General Practice
- Humans
- Hypercholesterolemia/complications
- Middle Aged
- Obesity/complications
- Retrospective Studies
- Risk Factors
- Romania/epidemiology
Collapse
Affiliation(s)
- Alina Manole
- Facultatea de Medicină, Disciplina de Asistenţa Primară a Stării de Sănătate si Epidemiologie, Universitatea de Medicină si Farmacie "Gr.T. Popa" Iaşi
| | | | | | | | | |
Collapse
|
48
|
Ying MG, Chen Q, Ye YB, Chen HJ, Chen X, Zheng HY, Wu F. [Application of serum proteomic mass spectrum analysis in breast cancer]. Zhonghua Zhong Liu Za Zhi 2010; 32:698-702. [PMID: 21122387] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
OBJECTIVE To analyze the characteristics of serum proteins mass spectra in healthy controls, benign breast tumors, and CA15-3 negative or CA15-3 positive breast cancer patients by surface enhanced laser desorption ionization time of flight mass spectrometry (SELDI-TOF-MS). METHODS Tissue samples of 113 cases of breast cancer (93 case of CA15-3 negative, 20 case of CA15-3 positive), 103 cases of benign breast tumor and 92 cases of healthy controls were examined and analyzed by SELDI and protein chip (CM10) techniques. Biomarker Pattern Software (BPS) was used to detect the protein peaks significantly different between them and establish a diagnostic pattern which was further evaluated by a blind test. RESULTS Twelve significantly different protein peaks were found in serum samples between breast cancer patients and healthy controls. Eleven significantly different peaks were found between benign breast tumor patients and healthy controls. By combined analysis of those three different protein mass spectra, the peak 15 952 was found to be significantly different between breast cancer group and healthy controls, and the peak 7985 was significantly different among breast cancer group, benign breast tumor group and health controls. The blind test with the differential proteins for the serum samples of 93 cases of CA15-3 negative breast cancer and 36 cases of benign breast tumors showed that the sensitivity was 80.6% and specificity was 91.7%. The blind test in 20 cases of CA15-3 positive breast cancer and 36 cases of benign breast tumors showed that the sensitivity was 75.0% and specificity was 91.7%. Four significantly different protein peaks were found between the benign breast tumor patients and CA15-3 negative breast cancer patients. No significantly different protein were found between CA15-3 negative and CA15-3 positive patients. CONCLUSION Significantly different protein peaks can be screened out in breast cancer, benign breast tumor patients and healthy controls by SELDI-TOF-MS analysis.
Collapse
Affiliation(s)
- Min-gang Ying
- Department of Surgery, Fujian Tumor Hospital, Fuzhou 350014, China.
| | | | | | | | | | | | | |
Collapse
|
49
|
Jing F, Yuping W, Yong C, Jie L, Jun L, Xuanbing T, Lihua H. CpG island methylator phenotype of multigene in serum of sporadic breast carcinoma. Tumour Biol 2010; 31:321-31. [PMID: 20490964 DOI: 10.1007/s13277-010-0040-x] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2010] [Accepted: 04/10/2010] [Indexed: 11/26/2022] Open
Abstract
CpG island methylator phenotype (CIMP) involves methylation targeted toward the promoters of multiple genes. We determined a methylation profile of tumor-related genes in serum of sporadic breast cancer (SBC). The multigene methylation was examined by methylation-specific polymerase chain reaction assay in serum of 50 SBCs and 50 paired nontumors, and CIMP+ was defined as having three genes that are concordantly methylated. The methylation frequency of ten genes in serum of 50 SBCs varied from 10% in FHIT to 74% in RASSF1A. The methylation status of RASSF1A, BRCA1, p16, CDH1, ER, RARbeta2, APC, and DAPK was significantly correlated with SBC and nontumor serum (P < 0.05). Methylation of at least one gene was found in 92% SBC; CIMP was more frequent in SBC than nontumor serum (P < 0.001). There was a significant association between CIMP and methylation of RASSF1A, BRCA1, p16, CDH1, ER, RARbeta2, APC, and DAPK (P < 0.05); the methylation link profile of CDH1, RASSF1A, BRCA1, and RARbeta2 as breast cancer marker may contribute high sensitivity (90%) and specificity (88%). ER and RARbeta2 methylation was associated with elevated serum CA153 levels in 39 SBC samples with CIMP+ (P < 0.05). Multivariate analysis showed that living area of patients was found to provide independent prognostic information associated with a relative risk of tumor recurrence of 5.3. Multigene-specific methylation profile in serum was association with the recurrence risk of rural SBC, and positive correlation of CIMP can serve as a promising molecular marker of SBC.
Collapse
MESH Headings
- Adult
- Aged
- Biomarkers, Tumor/genetics
- Breast Neoplasms/blood
- Breast Neoplasms/genetics
- Breast Neoplasms/pathology
- Carcinoma, Ductal, Breast/blood
- Carcinoma, Ductal, Breast/genetics
- Carcinoma, Ductal, Breast/pathology
- Carcinoma, Lobular/blood
- Carcinoma, Lobular/genetics
- Carcinoma, Lobular/pathology
- Case-Control Studies
- CpG Islands/genetics
- DNA Methylation
- DNA, Neoplasm/blood
- Epigenesis, Genetic
- Female
- Gene Expression Regulation, Neoplastic
- Humans
- Lymphatic Metastasis
- Middle Aged
- Multigene Family/genetics
- Neoplasm Invasiveness
- Phenotype
- Prognosis
- Promoter Regions, Genetic
- Young Adult
Collapse
Affiliation(s)
- Feng Jing
- Department of Laboratory Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | | | | | | | | | | | | |
Collapse
|
50
|
Corrado G, Garganese G, Fuoco G, Carbone A, Scambia G, Ferrandina G. Solitary pancreatic lymph node metastasis from carcinoma of the breast: case report. Diagn Pathol 2010; 5:29. [PMID: 20478044 PMCID: PMC2881069 DOI: 10.1186/1746-1596-5-29] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2010] [Accepted: 05/17/2010] [Indexed: 11/16/2022] Open
Abstract
BACKGROUND We report the first case of isolated pancreatic lymph node recurrence in a locally advanced breast cancer patient. CASE A 41-year old woman underwent radical mastectomy according to Madden and removal of axillary lymph nodes for multicentric infiltrating ductal carcinoma pathologically staged as pT2N2M0. After six years from primary diagnosis, and four years from the diagnosis of lung recurrence, she developed an isolated metastatic lesion to pancreatic lymph node. After surgical excision of metastasis, hormone therapy with Exemestane was begun. At 16 months of follow-up, the patient appears free of disease. CONCLUSION Because metastatization to visceral organ carries a very unfavorable prognosis, we think that the clinical significance of the elevation of CA 15.3 serum levels in the early detection of recurrence and in monitoring metastatic disease during follow-up, should be not underestimated.
Collapse
Affiliation(s)
- Giacomo Corrado
- Gynecologic Oncology Unit, Department of Oncology, Catholic University of the Sacred Heart, L.go A. Gemelli, 1 - 86100, Campobasso - Italy
| | - Giorgia Garganese
- Gynecologic Oncology Unit, Department of Oncology, Catholic University of the Sacred Heart, L.go A. Gemelli, 1 - 86100, Campobasso - Italy
| | - Gilda Fuoco
- Gynecologic Oncology Unit, Department of Oncology, Catholic University of the Sacred Heart, L.go A. Gemelli, 1 - 86100, Campobasso - Italy
| | - Arnaldo Carbone
- Institute of Human Pathology, Catholic University of the Sacred Heart, L.go A. Gemelli, 1 - 86100 Campobasso, Italy
| | - Giovanni Scambia
- Gynecologic Oncology Unit, Department of Oncology, Catholic University of the Sacred Heart, L.go A. Gemelli, 1 - 86100, Campobasso - Italy
| | - Gabriella Ferrandina
- Gynecologic Oncology Unit, Department of Oncology, Catholic University of the Sacred Heart, L.go A. Gemelli, 1 - 86100, Campobasso - Italy
| |
Collapse
|